The valve between the left atrium and left ventricle of the heart.
The blood pressure as recorded after wedging a CATHETER in a small PULMONARY ARTERY; believed to reflect the PRESSURE in the pulmonary CAPILLARIES.
The valve between the left ventricle and the ascending aorta which prevents backflow into the left ventricle.
A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material.
Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.
Abnormal protrusion or billowing of one or both of the leaflets of MITRAL VALVE into the LEFT ATRIUM during SYSTOLE. This allows the backflow of blood into left atrium leading to MITRAL VALVE INSUFFICIENCY; SYSTOLIC MURMURS; or CARDIAC ARRHYTHMIA.
Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic.
The science devoted to the comparative study of man.
The sciences dealing with processes observable in nature.
The comparative science dealing with the physical characteristics of humans as related to their origin, evolution, and development in the total environment.
The mouth, teeth, jaws, pharynx, and related structures as they relate to mastication, deglutition, and speech.
Remains, impressions, or traces of animals or plants of past geological times which have been preserved in the earth's crust.
Field of social science that is concerned with differences between human groups as related to health status and beliefs.
A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Compounds based on a seven-membered ring fused to a five-membered ring. Heat can rearrange them to NAPHTHALENES which have two fused six-membered rings. They are similar to guaiazulenes which are SESQUITERPENES with a six-membered ring fused to a five-membered ring.
Surgery performed on the heart.
Elements of limited time intervals, contributing to particular results or situations.
Unstable isotopes of chromium that decay or disintegrate emitting radiation. Cr atoms with atomic weights of 46-49, 51, 55, and 56 are radioactive chromium isotopes.
Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs.
Use of antibiotics before, during, or after a diagnostic, therapeutic, or surgical procedure to prevent infectious complications.
The protrusion of an organ or part of an organ into a natural or artificial orifice.
The downward displacement of the cuspal or pointed end of the trileaflet AORTIC VALVE causing misalignment of the cusps. Severe valve distortion can cause leakage and allow the backflow of blood from the ASCENDING AORTA back into the LEFT VENTRICLE, leading to aortic regurgitation.
Bony structure of the mouth that holds the teeth. It consists of the MANDIBLE and the MAXILLA.
Downward displacement of the UTERUS. It is classified in various degrees: in the first degree the UTERINE CERVIX is within the vaginal orifice; in the second degree the cervix is outside the orifice; in the third degree the entire uterus is outside the orifice.
A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.
Pathologic deposition of calcium salts in tissues.
A pathological constriction occurring in the region above the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.
Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).
Surgical insertion of synthetic material to repair injured or diseased heart valves.
A fetuin subtype that is synthesized by HEPATOCYTES and secreted into the circulation. It plays a major role in preventing CALCIUM precipitation in the BLOOD.
Device constructed of either synthetic or biological material that is used for the repair of injured or diseased blood vessels.
Polyester polymers formed from terephthalic acid or its esters and ethylene glycol. They can be formed into tapes, films or pulled into fibers that are pressed into meshes or woven into fabrics.
Homopolymer of tetrafluoroethylene. Nonflammable, tough, inert plastic tubing or sheeting; used to line vessels, insulate, protect or lubricate apparatus; also as filter, coating for surgical implants or as prosthetic material. Synonyms: Fluoroflex; Fluoroplast; Ftoroplast; Halon; Polyfene; PTFE; Tetron.
An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.
The plan and delineation of prostheses in general or a specific prosthesis.
Surgical insertion of BLOOD VESSEL PROSTHESES to repair injured or diseased blood vessels.
The aorta from the DIAPHRAGM to the bifurcation into the right and left common iliac arteries.
Exclusive legal rights or privileges applied to inventions, plants, etc.
Catheters designed to be left within an organ or passage for an extended period of time.
A flexible, tubular device that is used to carry fluids into or from a blood vessel, hollow organ, or body cavity.
A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth.
Stainless steel. A steel containing Ni, Cr, or both. It does not tarnish on exposure and is used in corrosive environments. (Grant & Hack's Chemical Dictionary, 5th ed)
The rotational force about an axis that is equal to the product of a force times the distance from the axis where the force is applied.
Artificial substitutes for body parts, and materials inserted into tissue for functional, cosmetic, or therapeutic purposes. Prostheses can be functional, as in the case of artificial arms and legs, or cosmetic, as in the case of an artificial eye. Implants, all surgically inserted or grafted into the body, tend to be used therapeutically. IMPLANTS, EXPERIMENTAL is available for those used experimentally.
Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function.
Adherence of cells to surfaces or to other cells.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.

Animal experimental implantation of an atrial septal defect occluder system. (1/2034)

OBJECTIVE: To establish the implantation technique for the atrial septal defect occluder system (ASDOS) device in an experimental animal model and to determine long term mechanical stability of the device and its in vivo properties in terms of biocompatibility and tissue reaction. MATERIALS AND METHODS: An atrial septal defect was created and the device implanted in 17 pigs (mean weight 30 kg). The implantation technique was refined and modified because of initial technical and anatomical complications during nine acute pilot studies. The technique proved to be feasible in eight subsequent survival studies. Four pigs were electively killed three months after implantation (group 1). The remaining four pigs were killed six months after implantation (group 2). RESULTS: Necropsy showed all devices were embedded in soft tissue three months after implantation. Microscopic examination of atrial septal tissue showed an acute granulomatous inflammatory reaction in group 1 and fibrosis in group 2. The intensity of the inflammatory reaction around the device was clearly milder in group 2, indicating a decline in the inflammatory response with time. Clinical and biochemical investigations indicated acceptable biocompatibility of the device. CONCLUSION: The implantation technique for the ASDOS device in a chronic pig model has been established. Biocompatibility of the device was acceptable.  (+info)

Bileaflet mechanical prostheses for aortic valve replacement in patients younger than 65 years and 65 years of age or older: major thromboembolic and hemorrhagic complications. (2/2034)

OBJECTIVE: To determine major thromboembolic and hemorrhagic complications and predictive risk factors associated with aortic valve replacement (AVR), using bileaflet mechanical prostheses (CarboMedics and St. Jude Medical). DESIGN: A case series. SETTING: Cardiac surgical services at the teaching institutions of the University of British Columbia. PATIENTS AND METHODS: Patients 2 age groups who had undergone AVR between 1989 and 1994 were studied. Group 1 comprised 384 patients younger than 65 years. Group 2 comprised 215 patients 65 years of age and older. RESULTS: The linearized rates of major thromboembolism (TE) occurring after AVR were 1.54%/patient-year for group 1 and 3.32%/patient-year for group 2; the rates for major TE occurring more than 30 days after AVR were 1.13%/patient-year for group 1 and 1.55%/patient-year for group 2. The crude rates for major TE occurring within 30 days of AVR were 1.04% for group 1 and 3.72% for group 2. The death rate from major TE in group 1 was 0.31%/patient-year and in group 2 was 0.88%/patient-year. Of the major TE events occurring within 30 days, 100% of patients in both age groups were inadequately anticoagulated at the time of the event, and for events occurring more than 30 days after AVR, 45% in group 1 and 57% in group 2 were inadequately anticoagulated (INR less than 2.0). The overall linearized rates of major hemorrhage were 1.54%/patient-year for group 1 and 2.21%/patient-year for group 2. There were no cases of prosthesis thrombosis in either group. The mean (and standard error) overall freedom from major TE for group 1 patients at 5 years was 95.6% (1.4%) and with exclusion of early events was 96.7% (1.3%); for group 2 patients the rates were 90.0% (3.2%) and 93.7% (3.0%), respectively. The mean (and SE) overall freedom from major and fatal TE and hemorrhage for group 1 patients was 90.1% (2.3%) and with exclusion of early events was 91.2% (2.3%); for group 2 patients the rates were 87.9% (3.1%) and 92.5% (2.9%), respectively. The 5-year rate for freedom from valve-related death for group 1 patients was 96.3% (2.1%) and for group 2 patients was 97.2% (1.2%). CONCLUSION: The thromboembolic and hemorrhagic complications after AVR with bileaflet mechanical prostheses occur more frequently and result in more deaths in patients 65 years of age and older than in patients years younger than 65 years.  (+info)

Minimally invasive aortic valve replacement through a transverse sternotomy: a word of caution. (3/2034)

OBJECTIVES: To compare aortic valve replacement (AVR) using a minimally invasive approach through a transverse sternotomy with the established approach of median sternotomy. DESIGN: Retrospective, case-control study. PATIENTS: Fourteen high risk patients (median age 78, Parsonnet score of 18%) who underwent AVR performed through a minimally invasive transverse sternotomy were compared with a historical group of patients matched for age, sex, and Parsonnet score who underwent AVR performed through a median sternotomy by the same surgeon. OUTCOME MEASURES: Cross clamp time, total bypass time, intensive care stay, postoperative in-hospital stay, morbidity, and mortality. RESULTS: There were two deaths in the minimally invasive group and none in the control group (NS). The cross clamp and total bypass times were longer in the minimally invasive group (67 and 92 minutes v 46 and 66 minutes, p < 0.001). There was a higher incidence of re-exploration for bleeding (14% v 0%) and paravalvar leaks (21% v 0%) in the minimally invasive group but these differences were not significant. The minimally invasive group had a longer postoperative in-hospital stay (p = 0.025). The incidence of mortality or major morbidity was 43% (six of 14) in the minimally invasive group and 7% (one of 14) in the matched pairs (p = 0.013). CONCLUSIONS: AVR can be performed through a transverse sternotomy but the operation takes longer and there is an unacceptably high incidence of morbidity and mortality.  (+info)

Perivalvular abscesses associated with endocarditis; clinical features and prognostic factors of overall survival in a series of 233 cases. Perivalvular Abscesses French Multicentre Study. (4/2034)

AIMS: The purposes of this study were to determine the clinical features and to identify prognostic factors of abscesses associated with infective endocarditis. METHODS AND RESULTS: During a 5-year period from January 1989, 233 patients with perivalvular abscesses associated with infective endocarditis were enrolled in a retrospective multicentre study. Of the patients, 213 received medical surgical therapy and 20 medical therapy alone. No causative microorganism could be identified in 31% of cases. Sensitivity for the detection of abscesses was 36 and 80%, respectively using transthoracic and transoesophageal echocardiography. Surgical treatment consisted of primary suture of the abscess (38%), insertion of a felt aortic or mitral ring using Teflon or pericardium (42%), or debridment of the abscess cavity (20%). The 1 month operative mortality was 16%. Actuarial rates for overall survival at 3 and 27 months in operated patients were 75 +/- 10% and 59 +/- 11%, respectively. Increasing patient age, staphylococcal infection, and fistulization of the abscess were found to be independent risk factors in both 1 month and overall operative mortality. Renal failure was a risk factor predictive of operative mortality at 1 month, whereas uncontrolled infection and circumferential abscess were regarded as risk factors predictive of overall operative mortality. CONCLUSION: The data determined prognostic factors of abscesses associated with infective endocarditis.  (+info)

Replacement of the aortic root in patients with Marfan's syndrome. (5/2034)

BACKGROUND: Replacement of the aortic root with a prosthetic graft and valve in patients with Marfan's syndrome may prevent premature death from rupture of an aneurysm or aortic dissection. We reviewed the results of this surgical procedure at 10 experienced surgical centers. METHODS: A total of 675 patients with Marfan's syndrome underwent replacement of the aortic root. Survival and morbidity-free survival curves were calculated, and risk factors were determined from a multivariable regression analysis. RESULTS: The 30-day mortality rate was 1.5 percent among the 455 patients who underwent elective repair, 2.6 percent among the 117 patients who underwent urgent repair (within 7 days after a surgical consultation), and 11.7 percent among the 103 patients who underwent emergency repair (within 24 hours after a surgical consultation). Of the 675 patients, 202 (30 percent) had aortic dissection involving the ascending aorta. Forty-six percent of the 158 adult patients with aortic dissection and a documented aortic diameter had an aneurysm with a diameter of 6.5 cm or less. There were 114 late deaths (more than 30 days after surgery); dissection or rupture of the residual aorta (22 patients) and arrhythmia (21 patients) were the principal causes of late death. The risk of death was greatest within the first 60 days after surgery, then rapidly decreased to a constant level by the end of the first year. CONCLUSIONS: Elective aortic-root replacement has a low operative mortality. In contrast, emergency repair, usually for acute aortic dissection, is associated with a much higher early mortality. Because nearly half the adult patients with aortic dissection had an aortic-root diameter of 6.5 cm or less at the time of operation, it may be prudent to undertake prophylactic repair of aortic aneurysms in patients with Marfan's syndrome when the diameter of the aorta is well below that size.  (+info)

Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. (6/2034)

OBJECTIVES: The purpose of this study was to assess the incidence of warfarin fetal complications and whether they are dose-dependent. BACKGROUND: Gravid patients with mechanical heart valves require long-term anticoagulant therapy. Controversy exists concerning the appropriate treatment of these patients. METHODS: Forty-three women on warfarin carrying out 58 pregnancies were studied. For each patient with full-term pregnancy a caesarian section was scheduled for the 38th week during brief warfarin discontinuation. Maternal and fetal complications were evaluated. Fetal complications were divided according to the warfarin dosage < or = 5 mg and > 5 mg necessary to keep an international normalized ratio (INR) of 2.5 to 3.5, and analyzed subsequently. RESULTS: A total of 58 pregnancies were observed: 31 healthy babies (30 full term, 1 premature) and 27 fetal complications (22 spontaneous abortions, 2 warfarin embryopathies, 1 stillbirth, 1 ventricular septal defect, 1 growth retardation) were recorded. Two maternal valve thromboses occurred. No fetal or maternal bleeding was observed during caesarian sections or premature vaginal delivery. Patients whose warfarin doses during pregnancy were > 5 mg had 22 fetal complications, whereas those taking a dose < or = 5 mg had only five fetal complications (p = 0.0001). For an increase of the warfarin dose there was a substantially increased probability of fetal complications (p < 0.0001; p < 0.7316). CONCLUSIONS: There is a close dependency between warfarin dosage and fetal complications. Patients on warfarin anticoagulation may be delivered by planned caesarian section at the 38th week while briefly interrupting anticoagulation.  (+info)

Acute renal failure following cardiac surgery. (7/2034)

BACKGROUND: Acute renal failure requiring dialysis (ARF-D) occurs in 1.5% of patients following cardiac surgery, and remains a cause of major morbidity and mortality. While some preoperative risk factors have been characterized, the influence of preoperative and intraoperative factors on the occurrence of ARF following cardiac surgery is less well understood. METHODS: Preoperative and intraoperative data on 2843 consecutive adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) from February 1, 1995 to February 1, 1997 were recorded and entered into a computerized database. Two definitions of renal failure were employed: (i) ARF defined as a rise in serum creatinine (Cr) of 1 mg/dl above baseline; and (ii) ARF-D defined as the development of ARF for which some form of dialytic therapy was required. The association between preoperative and intraoperative variables and the development of ARF was assessed by multivariate logistic regression. RESULTS: A total of 2672 of the 2844 patients underwent isolated coronary artery bypass grafting (CABG) surgery, the remaining 172 underwent valve surgery with or without bypass grafting. Of the CABG patients 7.9% developed ARF and 0.7% developed ARF-D. The mortality for patients who developed ARF was 14% (OR 15, P = 0.0001) compared with 1% among those who did not develop ARF. The mortality for CABG patients who developed ARF-D was 28% (OR 20, P = 0.0001) compared with 1.8% among those who did not require dialysis. Variables that were significantly associated with the development of ARF by multivariate analysis included: increased age, elevated preoperative serum Cr, duration of CPB, presence of a carotid artery bruit, presence of diabetes, reduced cardiac ejection fraction and increased body weight. Variables independently associated with ARF-D included serum Cr, duration of CPB, carotid artery bruit and presence of diabetes. The utility of these models for predicting the development of ARF and ARF-D was confirmed by bootstrapping techniques. Because of the small number of patients who underwent valve surgery, none of these variables were significantly associated with the development of ARF or ARF-D in this group of patients. CONCLUSION: The development of ARF or ARF-D is associated with a high mortality following CABG surgery. We have identified perioperative variables, which may be useful in stratifying risk for the development of ARF.  (+info)

The natural history of aortic valve disease after mitral valve surgery. (8/2034)

OBJECTIVES: The present study evaluates the long-term course of aortic valve disease and the need for aortic valve surgery in patients with rheumatic mitral valve disease who underwent mitral valve surgery. BACKGROUND: Little is known about the natural history of aortic valve disease in patients undergoing mitral valve surgery for rheumatic mitral valve disease. In addition there is no firm policy regarding the appropriate treatment of mild aortic valve disease while replacing the mitral valve. METHODS: One-hundred thirty-one patients (44 male, 87 female; mean age 61+/-13 yr, range 35 to 89) were followed after mitral valve surgery for a mean period of 13+/-7 years. All patients had rheumatic heart disease. Aortic valve function was assessed preoperatively by cardiac catheterization and during follow-up by transthoracic echocardiography. RESULTS: At the time of mitral valve surgery, 59 patients (45%) had mild aortic valve disease: 7 (5%) aortic stenosis (AS), 58 (44%) aortic regurgitation (AR). At the end of follow-up, 96 patients (73%) had aortic valve disease: 33 AS (mild or moderate except in two cases) and 90 AR (mild or moderate except in one case). Among patients without aortic valve disease at the time of the mitral valve surgery, only three patients developed significant aortic valve disease after 25 years of follow-up procedures. Disease progression was noted in three of the seven patients with AS (2 to severe) and in six of the fifty eight with AR (1 to severe). Fifty two (90%) with mild AR remained stable after a mean follow-up period of 16 years. In only three patients (2%) the aortic valve disease progressed significantly after 9, 17 and 22 years. In only six patients of the entire cohort (5%), aortic valve replacement was needed after a mean period of 21 years (range 15 to 33). In four of them the primary indication for the second surgery was dysfunction of the prosthetic mitral valve. CONCLUSIONS: Our findings indicate that, among patients with rheumatic heart disease, a considerable number of patients have mild aortic valve disease at the time of mitral valve surgery. Yet most do not progress to severe disease, and aortic valve replacement is rarely needed after a long follow-up period. Thus, prophylactic valve replacement is not indicated in these cases.  (+info)

OBJECTIVE: We sought to describe the results of transfemoral aortic valve implantation using either the Sapien prosthesis or the CoreValve System.. BACKGROUND: Results of transfemoral aortic valve implantation using both commercially available prostheses have rarely been studied.. PATIENTS: Of 236 patients at high-risk or with contraindications to surgery, consecutively referred for transcatheter aortic valve implantation between October 2006 and June 2009, 83 were treated with transfemoral aortic valve implantation. The Sapien was the only prosthesis available until May 2008 and, since then, was used as the first option, while the CoreValve System was used when contraindications to the Sapien prosthesis were present.. RESULTS: Patients were aged 81+/-9 years, 98% in New York Heart Association classes III/IV, with predicted surgical mortalities of 26+/-14% using the EuroSCORE and 15+/-8% using the Society of Thoracic Surgeons Predicted Risk of Mortality score. Seventy-two patients were treated ...
BACKGROUND New generation transcatheter heart valves (THV) may improve clinical outcomes of transcatheter aortic valve implantation. METHODS AND RESULTS In a nationwide, prospective, multicenter cohort study (Swiss Transcatheter Aortic Valve Implantation Registry, NCT01368250), outcomes of consecutive transfemoral transcatheter aortic valve implantation patients treated with the Sapien 3 THV (S3) versus the Sapien XT THV (XT) were investigated. An overall of 153 consecutive S3 patients were compared with 445 consecutive XT patients. Postprocedural mean transprosthetic gradient (6.5±3.0 versus 7.8±6.3 mm Hg, P=0.17) did not differ between S3 and XT patients, respectively. The rate of more than mild paravalvular regurgitation (1.3% versus 5.3%, P=0.04) and of vascular (5.3% versus 16.9%, P,0.01) complications were significantly lower in S3 patients. A higher rate of new permanent pacemaker implantations was observed in patients receiving the S3 valve (17.0% versus 11.0%, P=0.01). There were no ...
Get Transcatheter Aortic Valve Implantation cost from certified hospitals in Mumbai. Get assistance from medical experts to select best hospital for Transcatheter Aortic Valve Implantation in Mumbai
OBJECTIVES: The purpose of the present study was to test whether the cumulative knowledge from the field of transapical transcatheter aortic valve implantation, when incorporated into a structured training and then gradually dispersed by internal proctoring, might eliminate the negative effect of the learning curve on the clinical outcomes. METHODS: The present study was a retrospective, single-center, observational cohort study of prospectively collected data from all 500 consecutive high-risk patients undergoing transapical transcatheter aortic valve implantation at our institution from April 2008 to December 2011. Of the 500 patients, 28 were in cardiogenic shock. Differences during the study period in baseline characteristics, procedural and postprocedural variables, and survival were analyzed using different statistical methods, including cumulative sum charts. RESULTS: The overall 30-day mortality was 4.6% (95% confidence interval, 3.1%-6.8%) and was 4.0% (95% confidence interval, ...
TY - JOUR. T1 - Comparison of midterm outcomes of transcatheter aortic valve implantation in patients with and without previous coronary artery bypass grafting. AU - On behalf of the OCEAN-TAVI Investigators. AU - Kawashima, Hideyuki. AU - Watanabe, Yusuke. AU - Kozuma, Ken. AU - Kataoka, Akihisa. AU - Nakashima, Makoto. AU - Hioki, Hirofumi. AU - Nagura, Fukuko. AU - Nara, Yugo. AU - Shirai, Shinichi. AU - Tada, Norio. AU - Araki, Motoharu. AU - Naganuma, Toru. AU - Yamanaka, Futoshi. AU - Ueno, Hiroshi. AU - Tabata, Minoru. AU - Mizutani, Kazuki. AU - Higashimori, Akihiro. AU - Takagi, Kensuke. AU - Yamamoto, Masanori. AU - Hayashida, Kentaro. PY - 2018/4/21. Y1 - 2018/4/21. N2 - The midterm safety and feasibility of transcatheter aortic valve implantation (TAVI) for patients with a history of coronary artery bypass graft (CABG) and high operative risk are unclear. This study compared the midterm outcomes of patients undergoing TAVI with or without previous CABG surgery. Between October 2013 ...
TY - JOUR. T1 - Use of Double Stiff Wire Allows Successful Transfemoral Transcatheter Aortic Valve Implantation Through Extreme Thoracic Aorta Tortuosity. AU - Buzzatti, Nicola. AU - Mangieri, Antonio. AU - Cota, Linda. AU - Ruparelia, Neil. AU - Romano, Vittorio. AU - Alfieri, Ottavio. AU - Colombo, Antonio. AU - Montorfano, Matteo. PY - 2015/4/21. Y1 - 2015/4/21. KW - complication. KW - transcatheter aortic valve implantation. UR - http://www.scopus.com/inward/record.url?scp=84937484987&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84937484987&partnerID=8YFLogxK. U2 - 10.1161/CIRCINTERVENTIONS.114.002331. DO - 10.1161/CIRCINTERVENTIONS.114.002331. M3 - Article. C2 - 25794508. AN - SCOPUS:84937484987. VL - 8. JO - Circulation: Cardiovascular Interventions. JF - Circulation: Cardiovascular Interventions. SN - 1941-7640. IS - 4. M1 - e002331. ER - ...
Introduction Permanent pacemaker implantation (PPM) following transcatheter aortic valve implantation (TAVI) is a recognised complication. However, the higher pacing rate post CoreValve TAVI compared to SAVR (33% vs 8%) is a cause for concern. Several factors including pre-existing bundle branch block (BBB), larger valve size, post dilatation and low implantation have been shown to independently impact on an increased risk of PPM requirement. Depth of CoreValve implantation below the aortic annulus can result in compression of conduction tissue and heart block and is therefore an important predictor of PPM requirement. A modified delivery catheter (ACCUTRAK) was introduced to address this by providing more controlled release of the prosthesis, preventing low implantation, thereby reducing the pacing rate. We evaluated the pacing rate in our cohort of patients (pts) and the effect of the new Accutrak catheter on the pacing rate. ...
TY - JOUR. T1 - First in human percutaneous implantation of a balloon expandable transcatheter heart valve in a severely stenosed native mitral valve. AU - Guerrero, Mayra. AU - Greenbaum, Adam. AU - ONeill, William. PY - 2014/6/1. Y1 - 2014/6/1. N2 - Transcatheter implantation of a balloon expandable valve in calcified severely stenosed native mitral valves has recently been described. The two cases reported so far utilized the surgical transapical approach generally used for transapical transcatheter aortic valve replacement. A percutaneous approach has not been published. We report the first successful percutaneous implantation of a balloon expandable transcatheter valve in the native mitral valve without a surgical incision.. AB - Transcatheter implantation of a balloon expandable valve in calcified severely stenosed native mitral valves has recently been described. The two cases reported so far utilized the surgical transapical approach generally used for transapical transcatheter aortic ...
BACKGROUND: Transcatheter aortic valve implantation was developed to provide a therapeutic option for patients considered to be ineligible for, and to mitigate mortality and morbidity associated with, high-risk surgical aortic valve replacement.. METHODS AND RESULTS: The Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess initial post commercial clinical transcatheter aortic valve implantation results of the Edwards SAPIEN valve in consecutive patients in Europe. Cohort 1 consists of 1038 patients enrolled at 32 centers. One-year outcomes are presented. Patients with the transapical approach (n=575) suffered more comorbidities than transfemoral patients (n=463) with a significantly higher logistic EuroSCORE (29% versus 25.8%; P=0.007). These groups are different; therefore, outcomes cannot be directly compared. Total Kaplan Meier 1-year survival was 76.1% overall, 72.1% for transapical and 81.1% for transfemoral patients, and 73.5% of surviving patients ...
Background: Transfemoral access is regarded as the TAVI gold standard for the transcatheter aortic valve implantation (TAVI) procedure. However, other options for vascular access have developed in the last few years. Access via the carotid artery is one such alternative. Materials and methods: The study included 9 elderly patients who underwent transcarotid TAVI procedure at the Cardiac and Vascular Surgery Department of the Medical University of Gdańsk. Procedures were performed by a local Heart Team in a hybrid operating room under general anesthesia. Data was collected before the implantation and at discharge. Results: The mean patients age was 81 years of age (64-88) and the mean logistic EuroSCORE was 10.8 (7-16). Implantations were performed with 100% device success rate. Intra-operative valve-in-valve procedure was performed in one patient; there were no access-related and valve-related complications during the surgery. Post-procedural complications included minor bleeding, hematoma and ...
Vascular complications were a factor that tempered the enthusiasm of widespread adoption of transcatheter aortic valve replacement (TAVR) after the completion of the original PARTNER IB (The Placement of Aortic Transcatheter Valves IB) trial (1). In that trial, the rate of major vascular complications was 16.2%. This was not surprising given the need for a 22- or 24-F delivery sheath via a transfemoral approach only. This rate later decreased in a high risk cohort of patients (2). This was not only as a result of increased operator experience, but also because of the availability of an alternative access for patients with peripheral arterial disease. The transapical approach involved direct left ventricular puncture with placement of a 26-F delivery sheath, which allowed delivery of the valve. As TAVR became available commercially, additional access approaches were developed. The first of these, the transaortic approach, showed lower rates of combined bleeding and vascular events compared to a ...
A prospective multi-center trial of patients undergoing aortic valve replacement for severe aortic stenosis. Patient cohorts will include the following groups based on operative risk for surgical aortic valve replacement: inoperable, high surgical risk (STS ≥ 8%), and intermediate risk (STS = 4-8%).. The Edwards SAPIEN XT transcatheter heart valve (THV) system will be studied in patients deemed inoperable or intermediate risk. A subset of inoperable patients will be randomized to receive transcatheter aortic valve replacement (TAVR) with either the SAPIEN XT THV or the SAPIEN THV. The SAPIEN XT will be studied in intermediate risk patients randomized to receive TAVR with the SAPIEN XT or surgical AVR.. The Edwards SAPIEN 3 THV will be studied in a non-randomized fashion in patients from all three risk groups.. Data will be collected from all patients for up to five years following the valve replacement procedure. ...
A prospective multi-center trial of patients undergoing aortic valve replacement for severe aortic stenosis. Patient cohorts will include the following groups based on operative risk for surgical aortic valve replacement: inoperable, high surgical risk (STS ≥ 8%), and intermediate risk (STS = 4-8%).. The Edwards SAPIEN XT transcatheter heart valve (THV) system will be studied in patients deemed inoperable or intermediate risk. A subset of inoperable patients will be randomized to receive transcatheter aortic valve replacement (TAVR) with either the SAPIEN XT THV or the SAPIEN THV. The SAPIEN XT will be studied in intermediate risk patients randomized to receive TAVR with the SAPIEN XT or surgical AVR.. The Edwards SAPIEN 3 THV will be studied in a non-randomized fashion in patients from all three risk groups.. Data will be collected from all patients for up to five years following the valve replacement procedure. ...
Introduction: Readmission within 30 days of hospitalization (30dRA) is increasingly used as a metric for quality of care. Transcatheter aortic valve replacement (TAVR) is also increasing, but 30dRA following TAVR is not well-understood.. Hypothesis: The purpose of this study is to define the incidence, etiology, and resource utilization of 30dRA following TAVR.. Methods: We used the ICD-9-CM code for TAVR (35.05) to identify patients who underwent TAVR and survived to discharge in 2012, in the Agency for Healthcare Research and Qualitys Healthcare Cost and Utilization Projects State Independent Databases for 4 geographically distinct states: Florida, Massachusetts, New York, and Washington. The patients were divided into 2 groups: those with and without a 30dRA. Patients with a 30dRA for rehabilitation on the day of discharge were excluded. Approximately 8% of 30dRA were not captured because they occurred in the following year.. Results: The incidence of 30dRA following TAVR was 20.2% ...
To report the initial US experience with newly approved transcatheter aortic valve replacement, Mack and coauthors gathered outcome data, including all-cause in
The most frequent mechanism associated with coronary obstruction after TAVI has been the displacement of the calcified native cusp over the coronary ostium, and this has also been confirmed by the present review of the published data. In fact, no cases of coronary obstruction related to the struts of the transcatheter valve frame or to the cuff/leaflets of the transcatheter valve itself have been reported to date. Although the final mechanism leading to coronary obstruction after TAVI is well understood, the risk factors that predispose a patient to its occurrence remain largely unknown. A low position of the coronary ostia with respect to the aortic annulus has been highlighted as one of the most important factors contributing to this complication, and it has been suggested that a coronary ostia height cutoff ≤10 mm increases the risk of coronary obstruction during TAVI (41,42). In a recent post-mortem study, including 51 normal hearts, the mean LCA height, as determined by the LCA distance ...
The first-in-human transcatheter aortic valve implantation (TAVI) was successfully performed in 2002. In excess of 50,000 TAVI procedures have been performed to date using the Edwards SAPIEN or...
Advanced chronic kidney disease (CKD) is an independent predictor of mortality in patients undergoing transcatheter aortic valve implantation (TAVI). We aimed to identify predictors of 1-year mortality in patients after TAVI stratified by the presence or absence of advanced CKD (defined as estimated glomerular filtration rate ≤30 ml/min/1.73 m2 or permanent renal replacement therapy). Patients (n = 1204) from 10 centers in Europe, Japan, and Israel were included: 464 with and 740 without advanced CKD. Advanced CKD was associated with a 2-fold increase in the adjusted risk of 1-year all-cause death (p |0.001), and a 1.9-fold increase in cardiovascular death (p = 0.016). Interaction-term analysis was used to identify and compare independent predictors of 1-year mortality in both groups. Impaired left ventricular ejection fraction and poor functional class were predictive of death in the advanced CKD group (odds ratio [OR] 2.27, p = 0.002 and OR 3.87, p = 0.003, respectively) but not in patients without
The purpose of the study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe,...
David H. Adams, MD, national co-principal investigator for the CoreValve U.S. Pivotal Trial, presented study results showing minimally invasive transcatheter aortic valve replacement (TAVR) with the CoreValve System is superior to surgical aortic valve replacement (SAVR) at one year in patients with severe aortic stenosis who are considered high risk for surgery.. Dr. Adams presented the findings at a late-breaking clinical trial session at the 63rd Annual Scientific Session of the American College of Cardiology (ACC), and also published simultaneously in the New England Journal of Medicine (NEJM).. The CoreValve High Risk Study is the first prospective, randomized study to show any transcatheter aortic valve to be superior to surgery. The CoreValve System was approved by the U.S. Food and Drug Administration (FDA) in January 2014 for patients considered extreme risk for surgery; the device is not currently approved in the U.S. for use with patients at high risk.. The head-to-head study met its ...
Philip F, Wong GB, Rogers JH, Low RI, Southard JA. Aortic Root and Annular Anatomical Exclusion for Transcatheter Aortic Valve Implantation. TCT Scientific Sessions. San Francisco, CA. November 11-15, 2015.. Wong GB, Southard JA, Rogers JH, Smith TW, Philip F, Singh G, Latif S, Boyd WD, Atkins B, Low RI. Heart Rate Variability of the Aortic Regurgitation Index Following Transcatheter Aortic Valve Replacement. SCAI 2015 Scientific Sessions. San Diego, CA May 6-10, 2015.. Sarcon A, Ghadri JR, Wong GB, Luscher TF, Templin C, Amsterdam EA. Takotsubo cardiomyopathy associated with opiate withdrawal. Q J Med. 2014; 107: 301-302.. Singh GD, Wong GB, Southard JA, Amsterdam EA. Food for thought: Atrioventricular dissociation. Am J of Medicine. 2013; 126(12): 1050-1053.. Wong GB, Southard J, Rogers J, Singh G, Smith T, Armstrong E, Flores M, Boyd D, Low R. Heart Rate Variability of the Aortic Regurgitation Index Following Transcatheter Aortic Valve Replacement. SCAI 2013 Scientific Sessions. Orlando, FL ...
If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patients written consent to publication and send them to the editorial office before submitting your response [Patient consent forms] ...
We sought to analyze outcomes of women receiving balloon-expandable valves (BEV) or self-expanding valves (SEV) in contemporary transcatheter aortic valve implantation (TAVI). WIN TAVI (Womens INternational Transcatheter Aortic Valve Implantation) is the first all-female TAVI registry to study the safety and performance of TAVI in women. We compared women treated with BEV (n = 408, 46.9%) versus those treated with SEV (n = 461, 53.1%). The primary efficacy end point was the Valve Academic Research Consortium-2 (VARC-2) composite of 1-year all-cause death, stroke, myocardial infarction, hospitalization for valve-related symptoms or heart failure or valve-related dysfunction. Women receiving SEV had higher surgical risk scores, higher rate of previous stroke and pulmonary hypertension whereas women receiving BEV were more frequently denied surgical valve replacement due to frailty. BEV patients were less likely to require post-dilation and had significantly lower rates of residual aortic ...
Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement for inoperable or surgical high-risk patients with severe aortic stenosis (1-3). Post-procedural aortic regurgitation (PAR) is a common complication after TAVR. PAR has been reported in 65% to 96% of TAVR cases (1,4-7). In most cases, the grade of regurgitation is usually only mild. However, moderate and severe grades of PAR occur in 2% to 24% of patients (1,4-7). Multiple studies have demonstrated that moderate and severe grades of PAR are associated with worse clinical outcomes (4,6). Furthermore, the 2-year follow-up of the PARTNER (Placement of Aortic Transcatheter Valves) trial has suggested that even mild paravalvular regurgitation has been associated with increased mortality (3). However, reliable methods to diagnose PAR severity have not been established.. The aortic regurgitation (AR) index is 1 of the valuable prognostic parameters for PAR in a catheterization laboratory (8). However, ...
RESULTS: Valve-in-valve procedures were performed in 365 patients (96 initial registry, 269 continued access patients). Mean age was 78.9 ± 10.2 years, and mean Society of Thoracic Surgeons score was 9.1 ± 4.7%. At 30 days, all-cause mortality was 2.7%, stroke was 2.7%, major vascular complication was 4.1%, conversion to surgery was 0.6%, coronary occlusion was 0.8%, and new pacemaker insertion was 1.9%. One-year all-cause mortality was 12.4%. Mortality fell from the initial registry to the subsequent continued access registry, both at 30 days (8.2% vs. 0.7%, respectively; p = 0.0001) and at 1 year (19.7% vs. 9.8%, respectively; p = 0.006). At 1 year, mean gradient was 17.6 mm Hg, and effective orifice area was 1.16 cm(2), with greater than mild paravalvular regurgitation of 1.9%. Left ventricular ejection fraction increased (50.6% to 54.2%), and mass index decreased (135.7 to 117.6 g/m(2)), with reductions in both mitral (34.9% vs. 12.7%) and tricuspid (31.8% vs. 21.2%) moderate or severe ...
Methods and Results-This multicenter, propensity score-matched study compared hemodynamics and early clinical outcomes in 246 patients with an aortic annulus area ,400 mm2 undergoing transcatheter aortic valve replacement with either a self-expanding transcatheter heart valve (Symetis ACURATE neo, n=129) or a balloon-expandable transcatheter heart valve (Edwards SAPIEN 3, n=117). The 1:1 propensity score matching resulted in 92 matched pairs. For ACURATE neo versus SAPIEN 3-treated patients, 30-day mortality (0.0% versus 1.0%), 1-year mortality (8.3% versus 13.3%), incidence of stroke (3.3% versus 2.2%), life-threatening bleeding (1.1% versus 1.1%), and major vascular complications (2.2% versus 6.5%), as well as pacemaker implantation rate (12.0% versus 15.2%), were similar. Paravalvular regurgitation ≥moderate was rare in both groups (4.5% versus 3.6%). The ACURATE neo presented lower mean transvalvular gradients (9.3 versus 14.5 mm Hg; P,0.001), larger indexed effective orifice areas (0.96 ...
Transcatheter heart valve implantation techniques recently have been developed. The basic principle is based on fixation of a pericardial xenograft in a low-profile nitinol or steel stent that can be crimped onto a catheter. Because of the low profile of the stent, excellent hemodynamic function of these devices may be achieved. Access to the heart is gained by using a transfemoral or a transapical approach. Experimental studies on different approaches have been performed (5,6), and clinical feasibility studies in selected high-risk patients have been conducted (7-9). Recently the concept of transcatheter transapical aortic valve implantation has been proven clinically (10).. All of these nonconventional approaches aim at treating high-risk patients with degenerative valve disease. To minimize the reoperative risk for failed xenografts, the VinV concept was developed. This VinV concept takes advantage of recently developed transcatheter valve implantation techniques as well as clinical ...
Implantation was successful in 30 of 31 cases (aortic annulus diameter 24.7 ± 1.5 mm); THV dislodgement necessitated valve-in-valve implantation in one patient. Post-procedural aortic regurgitation was none/trace in 28 of 31 and mild in 3 of 31 patients. During follow-up, two patients underwent valvular reinterventions (surgical aortic valve replacement for endocarditis, valve-in-valve implantation for increasing paravalvular regurgitation). All-cause mortality was 12.9% and 19.3% at 30 days and 6 months, respectively. In the remaining patients, a significant improvement in New York Heart Association class was observed and persisted up to 6 months after TAVI.. ...
Despite the promising short-term results of the PARTNER trials,7 31 long-term outcomes after TAVR remain an ongoing concern. For instance, 2 to 5 year follow-up analysis of the PARTNER 2 trial31 demonstrated a higher incidence of all-cause mortality in the TAVR cohort. Many have postulated that the underlying reasons may include the increased likelihood of structural valve degeneration and paravalvular leakage associated with TAVR. Consistent with this hypothesis, the TAVR cohort in the PARTNER 2 trial had a greater need for repeat intervention and valve-in-valve TAVR. Unfortunately, the PARTNER trials did not separately compare TAVR with miAVR (as the surgical arm was inclusive of all approaches); therefore, leaving an important gap in the literature.. In our pooled analysis, the 30-day all-cause mortality did not differ significantly between both groups; however, midterm mortality was significantly higher in the TAVR cohort. It should be noted that none of the included studies independently ...
(EMAILWIRE.COM, July 19, 2019 ) OG Analysis, a global market research firm, has announced the release of their Global Transcatheter Heart Valve: By Product (Transcatheter aortic valve replacement, Transcatheter mitral valve and Transcatheter pulmonary valve replacement), By Surgical approach (Transfemoral...
Although the original VARC standardized endpoint definitions were fundamentally useful and have been widely adopted, growing experience with TAVI studies has identified some definitions as ambiguous, of limited clinical utility, or in need of updating or extension (5,6,63,64). This need provided the rationale for a VARC-2 document with such improvements and additions. As was the case with the original VARC process, it should be emphasized that this consensus manuscript is not intended to be a guidelines document, but rather a practical tool to facilitate and inform clinical research in TAVI.. Current clinical trials are focusing more on intermediate risk patients, and more studies are comparing TAVI with surgical AVR. Therefore, it becomes increasingly important to identify those patients who benefit from either treatment. Specific risk categories have been defined to allow universal clinical study designs and outcome comparisons.. Changes and additions that have been applied to improve the ...
Transcatheter aortic valve replacement (TAVR) is increasingly performed in patients who are at high surgical risk for surgical aortic valve replacement. The frequency of coronary artery disease is as high as 70 percent in patients with severe aortic stenosis. It is routine practice to perform preoperative coronary angiography and PCI in patients for whom TAVR is planned. However, many patients require post-TAVR coronary angiography and intervention. Depending on the type of the percutaneous valve, this may not be as easy as it is in the absence of a percutaneous valve. In this tip of the month, we discuss nuances and tips and tricks that can be employed for coronary angiography in these patients ...
At a median follow-up of 183 days (63-365) and 144 days (56-365), 50 patients (22%) died and 75 patients (33%) experienced MACE. A threefold increase in the rates for death and MACE was observed in patients above the median (M2 vs. M1) of CA125 (5.2 vs. 1.6 per 10 person-years and 8.3 vs. 3.3 per 10 person-years, respectively; p for both < 0.001). In a multivariable analysis adjusted for logistic EuroSCORE, New York Heart Association (NYHA) functional class III/IV, and device success, baseline values of CA125 (M2 vs. M1) independently predicted death (hazard ratio [HR], 2.18; 95% confidence interval [CI], 1.11-4.26; p = 0.023) and MACE (HR, 1.77; 95% CI, 1.05-2.98; p = 0.031). In the longitudinal analysis, InCA125 as a time-varying exposure, was highly associated with both endpoints: HR, 1.47; 95% CI, 1.01-2.14; p = 0.043 and HR, 2.26; 95% CI, 1.28-3.98; p = 0.005, for death and MACE, respectively. ...
There has been a lot of conjecture that transcatheter aortic valve replacement (TAVR) may one day replace open-heart surgical aortic valve replacement (SAVR). However, after attending the American College of Cardiology (ACC) 2016 meeting, it is evident that change will come much sooner than anyone anticipated. Wow is really the key summary I can offer regarding the TAVR vs. SAVR data presented at ACC. Three key presentations were all positive for TAVR, showing it is at least equal or superior to surgery. This is not bad for a new technology with largely inexperienced operators being able to perform as well or better than cardiac surgeons with decades of experience.. The Partner 2A trial for the Sapien XT showed that the second-generation TAVR device was equal to surgery in intermediate-risk surgical patients. It was pointed out by experts in numerous ACC sessions that if the two techniques are equal, the minimally invasive method will usually win out as a new standard of care. The improved ...
Background: The presence of mitral regurgitation (MR) is an independent predictor of mortality after conventional aortic valve replacement for aortic stenosis. The predictive value of pre-procedural MR on clinical outcome after TAVI is unknown.. Methods: 3,195 consecutive patients were enrolled between January 2010 and October 2011 in 33 centres. MR was graded according to pre-procedural transthoracic echocardiography (TTE) as none/trivial (=0), mild (=1), moderate (=2), moderate-to-severe (=3), or severe (=4). The mean age was 82±7 years; 49% were female and mean logistic EuroSCORE was 21.9±14.3. Balloon (BE) and self-expendable (SE) devices were implanted in 66.9% and 33.1% of patients, respectively. Approaches were transarterial (transfemoral: 74.6%; subclavian: 5.8%), transapical (17.8%), and transaortic (1.8%).. Results: Pre-procedural TTE showed no MR in 32% of cases, a grade 1 MR in 46% of cases, a grade 2 MR in 20% of cases and a grade 3-4 in 2% of cases. Procedural success rate was ...
Philip Green, Suzanne V. Arnold, David J. Cohen, Ajay J. Kirtane, Susheel K. Kodali, David L. Brown, Charanjit S. Rihal, Ke Xu, Yang Lei, Marian C. Hawkey, Rebeca J. Kim, Maria C. Alu, Martin B. Leon, Michael J. Mack ...
Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following Transcatheter Aortic Valve Replacement.
Edwards Lifesciences Corp. said it invested $35 million to gain an exclusive right to buy privately held Corvia Medical Inc., which makes implants to treat heart failure. Tewksbury, Mass.-based Corvias InterAtrial Shunt Device is approved in the European Union to treat heart failure with preserved or mildly reduced ejection fraction. The device is undergoing clinical trials in the U.S. to seek approval from the U.S. Food and Drug Administration. Irvine, Calif.-based Edwards Lifesciences also acquired certain assets of Mitralign Inc. including intellectual property and associated clinical and regulatory experience.. Tewksbury, Mass.-based Mitralign makes devices to treat functional mitral and tricuspid regurgitation, which are diseases resulting from dysfunctional valves within the heart. Edwards Lifesciences, which is focused on making medical devices for heart diseases, did not disclose additional terms of the transactions. The company added that the transactions are not expected to impact its ...
Surgical Aortic Valve Replacement (SAVR) vs Transcatheter Aortic Valve Implantation (TAVI): Results Comparison for Prosthesis-Patient Mismatch (PPM) - adjusted outcomes, including mortality, heart failure (HF) rehospitalization, stroke, and quality of life, at 1 year Reporter: Aviva Lev-Ari, PhD, RN J Am Coll Cardiol. 2018 Sep 18. pii: S0735-1097(18)38287-1. doi: 10.1016/j.jacc.2018.09.001. [Epub ahead of print] Prosthesis-Patient […]…
TY - JOUR. T1 - Prognostic value of pre-procedural left ventricular strain for clinical events after transcatheter aortic valve implantation. AU - Suzuki-Eguchi, Noriko. AU - Murata, Mitsushige. AU - Itabashi, Yuji. AU - Shirakawa, Kosuke. AU - Fukuda, Memori. AU - Endo, Jin. AU - Tsuruta, Hikaru. AU - Arai, Takahide. AU - Hayashida, Kentaro. AU - Shimizu, Hideyuki. AU - Fukuda, Keiichi. PY - 2018/10/1. Y1 - 2018/10/1. N2 - Background Transcatheter aortic valve implantation (TAVI) is an alternative therapy for surgically highrisk patients with severe aortic stenosis (AS). Although TAVI improves survival of patients with severe AS, the mechanism of this effect remains to be clarified. We investigated the effects of TAVI on left ventricular (LV) function and identified the predictive parameters for cardiac events after TAVI. Methods and results We studied 128 patients with severe symptomatic AS who underwent TAVI. Echocardiographic assessments were performed before and after TAVI. In addition to ...
TY - JOUR. T1 - Imaging Guidance for Transcatheter Aortic Valve Replacement. T2 - Is Transoesophageal Echocardiography the Gold Standard?. AU - Xu, Bo. AU - Mottram, Philip M.. AU - Lockwood, Siobhan. AU - Meredith, Ian T.. PY - 2017/10/1. Y1 - 2017/10/1. N2 - Transcatheter aortic valve replacement (TAVR) is traditionally performed under cardiac imaging guidance. In the early TAVR experience, intra-procedural transoesophageal echocardiography (TOE) is recommended to guide device deployment, in the context of general anaesthesia (GA). Intra-procedural TOE imaging is particularly useful during TAVR deployment as a contrast-saving strategy for patients with renal impairment. Evidence has emerged recently demonstrating that in selected patients, transthoracic echocardiography (TTE) can be used to provide intra-procedural guidance for TAVR. Additionally, there is a growing body of evidence supporting the performance of TAVR using fluoroscopy alone, without additional cardiac imaging. This article ...
Transcatheter Heart Valve Replacement and Repair Market 2026 report includes Segment savvy top to the base assurance on the reason of a few portions clubbed with exhibit size checks and gauges to screen the essential territories of industry improvement in detail. Whats more, an official blueprint gives nuances of the entire report such that dynamic gathering can quickly and clearly get an idea of the establishment information, consolidating examination and fundamental ends.. The study enormously protects a wide analysis of the Transcatheter Heart Valve Replacement and Repair market focusing on the strengths, threats, weaknesses, and opportunities for the global Transcatheter Heart Valve Replacement and Repair Market. Therefore, the Transcatheter Heart Valve Replacement and Repair Market study determines the insights of the industry and selective comments from experts all over the world.. Get a Sample Copy of the Report at: http://www.researchreportcenter.com/request-sample/1523043 ...
Transcatheter aortic valve replacement (TAVR) Market - Global Industry Analysis, Size, Share, Trends and Forecast, 2014 - 2022 Transcatheter aortic valve replacement (TAVR) Market - - Market research report and industry analysis - 10925577
According to the latest market report published by Persistence Market Research titled Global Transcatheter Heart Valve Replacement & Repair Market: Global Industry Analysis and Forecast, 2016 - 2026, the global transcatheter heart valve replacement & repair market is projected to expand at a CAGR of 13.9% during the forecast period (2016-2026).. Request for Report [email protected]://www.persistencemarketresearch.com/samples/11167. Transcatheter heart valve replacement is a relatively non-invasive procedure to repair the damaged heart valves with bioprosthetic valves for treatment of valvular heart disease namely aortic stenosis and mitral regurgitation among geriatric population. It is an alternative approach to conventional open heart surgery, especially for extremely high risk patients. Transcatheter heart valve replacement & repair market was valued at US$ 1,605.5 Mn in 2015 and the revenue is expected to increase to US$ 6,701.5 Mn by 2026 at a CAGR of 13.9% over the forecast period.. The report ...
Methods and Results-Data were obtained using the national inpatient sample between the years 2011 and 2014. We used the International Classification of Diseases, Ninth Edition, Clinical Modification procedure codes 350.5 and 350.6 to identify patients undergoing transcatheter aortic valve replacement. Primary outcome of interest was in-hospital mortality. A 2-tailed P value ,0.01 was considered to denote statistical significance for all analyses. We identified 42 189 patients who underwent transcatheter aortic valve replacement between the years 2011 and 2014. Of these, 62.1% (n=26 229) had no CKD/ESRD, 33.7% (n=14 252) had CKD, and 4% (n=1708) had ESRD. Patients with CKD or ESRD had greater in-hospital mortality, hospital length of stay, hemorrhage requiring transfusion, and permanent pacemaker implantation (P,0.001). ...
BACKGROUND: Patients undergoing surgical aortic valve replacement (SAVR) are considered at high risk of infective endocarditis (IE). However, data on the risk of IE following transcatheter aortic valve replacement (TAVR) are sparse and limited by the lack of long-term follow-up as well as a direct comparison with patients undergoing SAVR.. OBJECTIVES: This study sought to investigate the long-term incidence of IE in patients undergoing TAVR and to compare the long-term risk of IE with patients undergoing isolated SAVR.. METHODS: In this nationwide observational cohort study, all patients undergoing TAVR and isolated SAVR from January 1, 2008, to December 31, 2016, with no history of IE and alive at discharge were identified using data from Danish nationwide registries.. RESULTS: A total of 2,632 patients undergoing TAVR and 3,777 patients undergoing isolated SAVR were identified. During a mean follow-up of 3.6 years, 115 patients (4.4%) with TAVR and 186 patients (4.9%) with SAVR were admitted ...
Repair of the Transcatheter aortic valve is a minimally invasive procedure. This technique is used without removing it to treat or restore old and damaged aortic valve. The technique used to insert a new valve to the place of the old aortic valve is called the Transcatheter aortic valve replacement system. Between the left atrium and the left ventricle is the mitral valve. Mitral valve disorder is a condition in which the valve ceases working properly, leading to abnormal blood flow. This abnormal blood flow can lead to diseases such as prolapse of the mitral valve and regurgitation of the mitral valve.. Renub Research latest study report Transcatheter Heart Valve Replacement Market, Volume, Share by Materials (Mechanical and Tissue) Position (Transcather Mitral Valve Replacement and Transcatheter Aortic Valve Replacement), Region (United States, Germany, China, France, Italy, Japan, Spain, United Kingdom, India and Brazil), Company Analysis provides a detailed and comprehensive insight of the ...
Transcatheter Aortic Valve Implantation has become an alternative treatment for elderly patients with severe aortic stenosis at risk of surgical aortic valve replacement
Currently, aortic valve replacement procedures require a sternotomy and use of cardiopulmonary bypass (CPB) to arrest the heart and provide a bloodless field in which to operate. A less invasive alternative to open heart surgery is transapical or transcatheter aortic valve replacement (TAVR), already emerging as a feasible treatment for patients with high surgical risk. The bioprosthetic valves are delivered via catheters using transarterial or transapical approaches and are implanted within diseased aortic valves. This paper reports the development of a new self-expanding stent for minimally invasive aortic valve replacement and its delivery device for the transapical approach under real-time magnetic resonance imaging (MRI) guidance. Made of nitinol, the new stent is designed to implant and embed a commercially available bioprosthetic aortic valve in aortic root. An MRI passive marker was affixed onto the stent and an MRI active marker to the delivery device. These capabilities were tested in ...
The hypothesis of this study was that local anesthesia with monitored anesthesia care (MAC) is not harmful in comparison to general anesthesia (GA) for patients undergoing Transcatheter Aortic Valve Implantation (TAVR). TAVR is a rapidly spreading treatment option for severe aortic valve stenosis. Traditionally, in most centers, this procedure is done under GA, but more recently procedures with MAC have been reported. This is a systematic review and meta-analysis comparing MAC versus GA in patients undergoing transfemoral TAVR. Trials were identified through a literature search covering publications from 1 January 2005 through 31 January 2013. The main outcomes of interest of this literature meta-analysis were 30-day overall mortality, cardiac-/procedure-related mortality, stroke, myocardial infarction, sepsis, acute kidney injury, procedure time and duration of hospital stay. A random effects model was used to calculate the pooled relative risks (RR) with 95% confidence intervals. Seven observational
Transcatheter aortic valve implantation for failing surgical aortic bioprosthetic valve: from concept to clinical application and evaluation (part 2). JACC Cardiovasc Interv. 2011 Jul; 4(7):733-42 ...
Edwards SAPIEN XT transcatheter heart valve with the NOVAFLEX+ delivery system. Indications: The Edwards SAPIEN XT transcatheter heart valve is indicated for use in patients with symptomatic heart disease due to either severe native calcific aortic stenosis or failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., Society of Thoracic Surgeons operative risk score ≥ 8% or at a ≥ 15% risk of mortality at 30 days).. Contraindications: The THV and delivery systems are contraindicated in patients who cannot tolerate an anticoagulation/antiplatelet regimen or who have active bacterial endocarditis or other active infections.. Warnings: Observation of the pacing lead throughout the procedure is essential to avoid the potential risk of pacing lead perforation. There is an increased risk of stroke in transcatheter aortic valve replacement ...
TCT-748 First Human Cohort Transcatheter Aortic Valve Implantations Of The Colibri Heart Valve, A Pre-Mounted, Pre-Packaged, Low Profile Ready for Use, Dry Valve In A 14 French Delivery System. Fifteen months of Follow Up ...
ABSTRACT: The optimal treatment for coronary artery disease in patients who are candidates for percutaneous aortic valve implantation (PAVI) remains unclear. The operating team should take into consideration that the symptoms of ischemic heart disease could be identical to those of severe aortic stenosis and that performing percutaneous coronary intervention (PCI) in these frail patients prior to, or following PAVI, is not trivial. We describe a patient with severe aortic stenosis and significant coronary artery disease who was treated during the same interventional session: PCI that was followed immediately by PAVI. We review the different treatment strategies for patients who are candidates for PAVI and have coronary artery disease, discuss the relative advantages of each approach, and propose an algorithm for their treatment. _______________________________________________. J INVASIVE CARDIOL 2009;21:E237-E241. Key words: PaceC elevation. Calcific aortic stenosis is associated with ...
Minimally invasive aortic valve replacement versus aortic valve replacement through full sternotomy: the Brigham and Womens Hospital experience
Predilatation has been historically considered a mandatory step before transcatheter aortic valve implantation (TAVI) since it facilitates valve crossing and prosthesis delivery, ensures optimal valve expansion and improves hemodynamic stability during valve deployment.
Adequate presentation of risks and benefits of medical therapies is essential to informed decision making by patients. Transcatheter aortic valve replacement (T
BACKGROUND: Aortic regurgitation (AR) is an important limitation of transcatheter aortic valve replacement (TAVR) with ill-defined predictors and unclear long term impact on outcomes. We sought to analyze currently published literature to establish t
Introduction The development of transcatheter aortic valve replacement (TAVR) can certainly be considered one of the most fascinating examples of successful translational research in medicine. Thanks to an outstanding partnership between multidisciplinary clinicians and engineers, we could move from concept to bench, bench to bedside, bedside to clinical feasibility trials, then on to larger clinical registries and evidence based trials, leading ultimately to a breakthrough technology with durable impact on the pattern of medical practice. This disruptive technology evoked scepticism and criticism in the beginning, but thanks to innumerable clinical trials and evidence based investigations, it is now widely accepted by the medical community and its acceptance is continuing to grow. In the last fourteen years, TAVR has been performed in around 300,000 patients in 65 countries and adoption is increasing by 40% year on year. The field of TAVR is rapidly evolving, with major
Trans-apical Transcatheter Aortic Valve Replacement in a Patient with Severe and Complex Left Main Coronary Artery Disease (LMCAD) Writer: Larry H Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN Significant, defined as a greater than 50 percent narrowing, left main coronary artery disease (LMCAD) is found in 4 to 6 percent of all patients who…
This report provides in-depth analysis of the Global Transcatheter Aortic Valve Replacement (TAVR) Market in terms of value and segments. Also assesses the key opportunities in this (TAVR) Market and outlines the factors that are and will be driving the growth of the industry..
Valve replacement surgery has a high rate of success and a low risk of causing other problems if you are otherwise healthy. Although most people have successful outcomes, there is a risk of death and serious problems during surgery. Valve replacement surgery is high-risk for people who have a failing left ventricle and who have had a heart attack. About 5 or less out of 100 people who have valve surgery die.footnote 3. If you have severe aortic valve regurgitation or stenosis, the risks of not replacing the valve may be greater than the risks of surgery, unless you have other health problems that make surgery too dangerous.. Even if valve replacement surgery is a success, you may have problems after surgery, such as:. ...
One of our new heart treatments is the Transcatheter aortic valve replacement. It is one of the minimally invasive heart procedures. Find out more.
【 Essay on Transcatheter Aortic Valve Replacement 】for free from best writers of Artscolumbia ✅ Largest assortment of free essays ✅ Find what you need here!
Transfemoral aortic valve implantation (TAVI) is the most commonly adopted access for TAVI, as vascular injury and complication remain a concern that affects both procedural and clinical outcomes, so...
The valve-in-valve concept is an emerging therapeutic option for patients with degenerative failure of previously implanted xenografts. Reoperation of degenerated bioprostheses has a high mortality risk that increases with the age and associated comorbidities of the patients. The transcatheter valve-in-valve implantation does not need resternotomy or cardiopulmonary bypass, potentially reducing the morbidity and mortality risk. However, unlike the transcatheter implants in native valves, in the valve-in-valve procedures, the leaflets and calcified annulus are replaced with the rigid annulus of the xenograft. This requires accurate sizing of the transcatheter valve, currently available in 2 sizes. Therefore, 3-dimensional imaging techniques, particularly multi-detector row computed tomography (MDCT), may provide a more exact sizing of the host xenograft ring. We report a mitral valve-in-valve procedure in a 79-year-old female patient with previous aortic and mitral valve replacement (a 21-mm and ...
Aortic annular rupture is a potentially fatal complication after transcatheter aortic valve implantation with high mortality. Although it is quite rare and difficult to identify the mechanisms and predictors, prosthesis oversizing and massive calcification of the aortic annulus are thought to be a potential risk of this complication. A case presented here is an aortic annular rupture after transcatheter aortic valve implantation. Although the valve was not oversized, there were 2 severe calcifications of aortic annulus at nearby areas like twin icicles, thought to be a trigger of this potentially fatal complication.Aortic annular rupture is a potentially fatal complication after transcatheter aortic valve implantation with high mortality. Although it is quite rare and difficult to identify the mechanisms and predictors, prosthesis oversizing and massive calcification of the aortic annulus are thought to be a potential risk of this complication. A case presented here is an aortic annular ...
Bioprosthetic valves are increasingly used in preference to mechanical valves in open SAVR, as lifelong oral anticoagulation is not required and its attendant complications can be avoided. A recent study has shown similar long-term survival rates in patients with bioprosthetic and mechanical valves. However, patients with bioprosthetic valves require reoperations due to their limited durability and expected degeneration;(12) those undergoing such reoperations face increased surgical risk due to their more advanced age (compared with their age during the index SAVR) during the redo surgery and scarring in the non-virgin chest. Consequently, valve-in-valve TAVI appears to be an attractive, minimally invasive method of replacing the degenerated surgical aortic bioprosthesis without the need for a reoperation. Several small case series and a global registry have shown that it is a feasible and viable option for patients at high risk.(5-9). In our initial Asian experience of valve-in-valve TAVI in ...
Objectives. To describe short-term clinical and echocardiography outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). To explore patient selection criteria for treatment with TAVI. Design. TAVI patients (n = 45) were matched to SAVR patients (n = 45) with respect to age within +/- 10 years, sex and systolic left ventricular function. Results. TAVI patients were older, 82 +/- 8 versus 78 +/- 5 years (p = 0.005) and they had higher logEuroSCORE, 16 +/- 11% versus 8 +/- 4% (p andlt; 0.001). There were no significant differences in 30 days mortality, stroke and myocardial infarction. TAVI patients received less erythrocyte (53% vs. 78%, p = 0.03) and thrombocyte (7% vs. 27%, p = 0.02) transfusions. Postoperative atrial fibrillation was less common (18% vs. 60%, p andlt; 0.001) in the TAVI group. Paravalvular regurgitation was more common in TAVI patients (87% vs. 0%, p andlt; 0.001) and 27% had access site complications. Aortic ...
A SWOT Analysis of Transcatheter Heart Valve Replacement and Repair, Professional Survey Report Including Top Most Global Players Analysis with CAGR and Stock Market Up and Down. The global Transcatheter Heart Valve Replacement and Repair market research report is crafted with the concise assessment and extensive understanding of the realistic data of the global Transcatheter […]. ...
A SWOT Analysis of Transcatheter Heart Valve Replacement and Repair, Professional Survey Report Including Top Most Global Players Analysis with CAGR and Stock Market Up and Down. The global Transcatheter Heart Valve Replacement and Repair market research report is crafted with the concise assessment and extensive understanding of the realistic data of the global Transcatheter […]. ...
Press Release issued Feb 23, 2017: According to the latest market report published by Persistence Market Research titled Global Transcatheter Heart Valve Replacement & Repair Market: Global Industry Analysis and Forecast, 2016 - 2026, the global transcatheter heart valve replacement & repair market is projected to expand at a CAGR of 13.9% during the forecast period (2016-2026).
The Edwards SAPIEN 3 Transcatheter Heart Valve System and Edwards SAPIEN 3 Ultra Transcatheter Heart Valve System are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy.. The Edwards SAPIEN 3 Transcatheter Heart Valve System and Edwards SAPIEN 3 Ultra Transcatheter Heart Valve System are indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic or mitral valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the STS risk score and other clinical co-morbidities unmeasured by the STS risk calculator).. Contraindications (Who should not use): ...
BIBA Research, the UK-based market research specialists for the medical technology industry, is set to present the latest findings of its Transcatheter Heart Valve (TAVI) report on April 26. The report covers the data period January-March 2010 and is part of BIBA Researchs long-established European Cardiovascular Monitor. BIBA Research said that the monitor on transcatheter heart valve was launched in coincidence with the TCT Conference in San Francisco previous year and represents the third-party investigation on market trends and penetration of transcatheter heart valve replacement and repair technologies in West Europe. The monitor tracks quarterly device consumption from a panel of over 300 hospitals in 15 countries. As per the research, Transcatheter (also known as percutaneous) heart valve implantation has one of the growth potentials in medical technology. The implantation of an aortic valve in humans was performed by Alain Cribier, French cardiologist, in 2002. Since then, transcatheter ...
... cochlear implantation MeSH E04.650.230 - dental implantation MeSH E04.650.410 - heart valve prosthesis implantation MeSH ... heart-lung transplantation MeSH E04.100.376.485 - heart valve prosthesis implantation MeSH E04.100.376.719 - myocardial ... heart-lung transplantation MeSH E04.928.220.410 - heart valve prosthesis implantation MeSH E04.928.220.520 - myocardial ... auditory brain stem implantation MeSH E04.650.200 - blood vessel prosthesis implantation MeSH E04.650.210 - breast implantation ...
"Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis". Circulation. 106 (24): ... Alain Cribier, Who Pioneered Heart Valve Replacement with Catheter, Receives Texas Heart Institute's Ray C. Fish Award for ... Alain Cribier, Who Pioneered Heart Valve Replacement with Catheter, Receives Texas Heart Institute's Ray C. Fish Award for ... Alain Cribier, Who Pioneered Heart Valve Replacement with Catheter, Receives Texas Heart Institute's Ray C. Fish Award for ...
"Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with ... "Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis. First human case ... When the valve is not inserted correctly, when there is incomplete sealing between the native heart valve and the stented valve ... is the replacement of the aortic valve of the heart through the blood vessels (as opposed to valve replacement by open heart ...
1971 Ionescu in Leeds, England, creates the first bovine pericardial heart valve and begins its implantation in humans. 1980 ... Pericarbon pericardial Valve prosthesis: an experience based on the lessons of the past' Annals of Thoracic Surgery 71, S289- ... Mitoflow pericardial heart valves: A 7 year clinical experience' In: Bodnar E (Ed) Surgery for heart Valve Disease. Proceedings ... A short history of the introduction in clinical use of valves made of animal tissue for heart valve replacement in humans ...
The first implantation of the caged ball heart valve, developed by Drs. Dwight E. Harken and William C. Birtwell, was made on ... who had implanted in her a prosthesis, made of polyurethane and Dacron, and designed by Drs. Nina Braunwald and Andrew Morrow. ... Died: American opera singer Leonard Warren, 48, suffered a heart attack while performing at the Metropolitan Opera in New York ... The next day, a 44-year-old woman received the valve and made a full recovery eight weeks later. ...
Further prostheses for mitral und tricuspid valve replacement are under development and certainly will be available within the ... 2008). Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association ... are repaired on a beating heart in combination with purely interventional techniques (e.g. MitralClip). From an imaging ... However, TAVI (transcatheter aortic valve implantation) has emerged as a valid alternative for patients in whom conventional ...
Bloomfield, P. (2002-06-01). "Choice of heart valve prosthesis". Heart. 87 (6): 583-589. doi:10.1136/heart.87.6.583. PMC ... transcatheter aortic valve implantation). Rather than removing the existing valve, this technique pushes a new valve into the ... Aortic valve repair Artificial heart valve Valvular heart disease Minimally invasive cardiac surgery Pericardial heart valves ... There are two basic types of replacement heart valve: tissue (bioprosthetic) valves and mechanical valves. Tissue heart valves ...
... valve. References[edit]. General references[edit]. *George B. Griffenhagen and Calvin H. Hughes. The History ... First clinical implantation of a total artificial heart[edit]. On April 4, 1969, Domingo Liotta and Denton A. Cooley replaced a ... "The Carmat Heart,- The technology behind the prosthesis". Archived from the original on 2013-06-29.. ... An artificial heart is a device that replaces the heart. Artificial hearts are typically used to bridge the time to heart ...
Heart transplantation (37.52) Implantation of total replacement heart system Artificial heart (37.6) Implantation of heart and ... Replacement of heart valve (35.3) Operations on structures adjacent to heart valves (35.4) Production of septal defect in heart ... Fitting of external prosthesis of penis Penlie prosthesis NOS (64.95) Insertion or replacement of non-inflatable penlie ... Operations on valves and septa of heart (35.0) Closed heart valvotomy (35.1) Open heart valvuloplasty without replacement (35.2 ...
Bloomfield P (June 2002). "Choice of heart valve prosthesis". Heart. 87 (6): 583-9. doi:10.1136/heart.87.6.583. PMC 1767148. ... "Polymeric heart valves for surgical implantation, catheter-based technologies and heart assist devices". Biomaterials. 36: 6-25 ... The human heart contains four valves: tricuspid valve, pulmonary valve, mitral valve and aortic valve. Their main purpose is to ... An artificial heart valve should ideally function like a natural heart valve. The functioning of natural heart valves is ...
Cardiovascular-related artificial organs are implanted in cases where the heart, its valves, or another part of the circulatory ... Simmons, M.; Montague D.K. (2008). "Penile prosthesis implantation: Past, present, and future". International Journal of ... The artificial heart is typically used to bridge the time to heart transplantation, or to permanently replace the heart in case ... without the removal of the heart itself. Besides these, lab-grown hearts and 3D bioprinted hearts are also being researched. ...
First clinical implantation of a total artificial heartEdit. On 4 April 1969, Domingo Liotta and Denton A. Cooley replaced a ... "The Carmat Heart,- The technology behind the prosthesis". Archived from the original on 29 June 2013.. ... The Carmat device also uses valves made from cow heart tissue and has sensors to detect increased pressure within the device. ... An artificial heart is a device that replaces the heart. Artificial hearts are typically used to bridge the time to heart ...
The technology behind the prosthesis". Archived from the original on 29 June 2013. "First-in-man implantation of CARMAT's ... Artificial heart valve George B. Griffenhagen and Calvin H. Hughes. The History of the Mechanical Heart. Smithsonian Report for ... An artificial heart is a device that replaces the heart. Artificial hearts are typically used to bridge the time to heart ... "Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy". 11 May 2017. "Implantation of Carmat's Artificial Heart ...
... surgery Bone cement Artificial ligaments and tendons Dental implants for tooth fixation Blood vessel prostheses Heart valves ... Surgical implantation of a biomaterial into the body triggers an organism-inflammatory reaction with the associated healing of ... The most widely used valve is a bileaflet disc heart valve or St. Jude valve. The mechanics involve two semicircular discs ... Such functions may be relatively passive, like being used for a heart valve, or maybe bioactive with a more interactive ...
... valvular heart disease, angina pectoris, and atherosclerosis. Examples include the artificial heart, artificial heart valve, ... Simmons M, Montague D (2008). "Penile prosthesis implantation: past, present, and future". International Journal of Impotence ... and artificial heart valves, such as the Bjork-Shiley valve, all of which have caused FDA intervention. The consequences of ... Thus, heart valve failure is likely to threaten the life of the individual, while breast implant or hip joint failure is less ...
It is one of the two semilunar valves of the heart, the other being the pulmonary valve. The heart has four valves; the other ... or TAVI transcatheter aortic valve implantation delivers a prosthetic valve through a catheter. The choice between SAVR and ... A replaceable model of Cardiac Biological Valve Prosthesis. Front of thorax, showing surface relations of bones, lungs (purple ... The shape of these valves do not mimic normal heart valves. Tissue heart valves are usually made from animal tissues, either ...
The pulmonary valve then needs to be replaced by a heart valve prosthesis. A drawback of this method is that it can frequently ... Transcatheter aortic valve implantation using anatomically oriented, marrow stromal cell-based, stented, tissue-engineered ... Biological prostheses, i.e. pericardial heart valves of animal origin (xenogenic), offer a viable alternative. However, in ... The lack of durable heart valve prostheses for young patients has driven forward research in tissue engineering approaches for ...
... and infections of permanent indwelling devices such as joint prostheses, heart valves, and intervertebral disc. The first ... 60-70% of hospital-acquired infections are associated with the implantation of a biomedical device. This leads to 2 million ... Biofilms often form on the inert surfaces of implanted devices such as catheters, prosthetic cardiac valves and intrauterine ... "Research on microbial biofilms (PA-03-047)". NIH, National Heart, Lung, and Blood Institute. 2002-12-20. Rogers A (2008). ...
Simon similarly used SynerGraft decellularized pig valves for implantation in children; however, these valves widely failed as ... "Biodegradable polymer with collagen microsponge serves as a new bioengineered cardiovascular prosthesis". The Journal of ... Tissue engineered heart valves (TEHV) offer a new and advancing proposed treatment of creating a living heart valve for people ... Tissue engineered heart valves offer certain advantages over traditional biological and mechanical valves: Living valve - The ...
In May 2017 the company acquired Symetis SA, a developer of minimally invasive transcatheter aortic valve implantation devices ... Johnson were involved in a series of litigations involving patents covering heart stent medical devices. Both parties claimed ... textile vascular prostheses), EPTechnologies (cardiac ablation controllers), MinTec (abdominal aortic aneurysm grafts), ... In October Boston announced it had invested further in percutaneous mitral valve replacement system developer, MValve ...
"Choice of heart valve prosthesis". Heart. 87 (6): 583-9. doi:10.1136/heart.87.6.583. PMC 1767148. PMID 12010950.. ... "Polymeric heart valves for surgical implantation, catheter-based technologies and heart assist devices". Biomaterials. 36: 6-25 ... Schmidt, Jillian B.; Tranquillo, Robert T. (2013). Tissue-Engineered Heart Valves. Heart Valves. Boston, MA: Springer US. str. ... "Assessment of a novel stentless mitral valve using a pulsatile mitral valve simulator". The Journal of Heart Valve Disease. 21 ...
Biological Tissue in Heart Valve Replacement, Butterworths, (1972), London, pages 467-513. Ionescu M I, Ross D N, "Heart Valve ... He began the clinical implantation of these valves in April 1969. This procedure of valve construction and implantation had ... Thamilarasan N, Griffin B, (2002), "Choosing The Most Appropriate Heart Operation and Prosthesis", Cleveland Clinic Journal of ... "Fascia Lata Heart Valves", In: Ionescu M I,Ross D N, Wooler G H, Eds. Biological Tissue in Heart Valve Replacement Butterworths ...
... blood continues to flow from the heart through the aortic valve. In addition, blood flow bypasses the native valve and exits ... MRI of the heart following implantation of a left ventricular apico‐aortic conduit. Rofo 2007 Jun;179(6):566‐71 Vassiliades TA ... Templeton implanted prostheses similar to those originally described by Sarnoff in five patients with severe aortic valve ... AAC avoids the risk of leakage around a replacement heart valve (aortic insufficiency), a serious complication of alternate ...
... pumps and valves. However, there are some drawbacks to using silicon-based devices in biomedical applications such as their ... improve prostheses, and monitor clinical parameters. Microfabrication has led to the development of Michigan probes and the ... flexible substrates has led to the development of a cardiac patch that adheres to the curvilinear surface of the heart by ... while addressing problems of thick substrates causing damage during implantation and triggering foreign-body reaction and ...
Silzone heart valve: St. Jude Medical released a mechanical heart valve with a silver coated sewing cuff (coated using ion beam ... Ion implantation[edit]. Ion implantation has been used to create silver nanoparticles embedded in glass, polyurethane, silicone ... Jude medical prosthesis with and without silzone-coated sewing cuffs". The Annals of Thoracic Surgery. 71 (3): 1065. doi: ... however it can be broken down into a few different sub-processes such as implantation, diffusion, and growth. Upon implantation ...
Mechanical stimuli, such as pressure pulses seem to be beneficial to all kind of cardiovascular tissue such as heart valves, ... synthetic ophthalmic prosthesis The first modern use of the term as recognized today was in 1985 by the researcher, ... prior to implantation significantly improves the performance of the created 3D scaffolds. The achieved biocompatibility was ... bioartificial heart: Doris Taylor's lab constructed a biocompatible rat heart by re-cellularizing a de-cellularized rat heart. ...
... an abnormal narrowing of the aortic valve in the heart. Video-assisted minilaparotomy surgery Koon Ho Rha and Seung Choul Yang ... Stent implantation of left main coronary artery stenosis Park Seung-jung pioneered a new method using a stent as an alternative ... "Stretchable silicon nanoribbon electronics for skin prosthesis". Nature Communications. 5: 5747. Bibcode:2014NatCo...5.5747K. ... "Innovator of alternative heart surgery". The Korea Times. 29 November 2015. Retrieved 3 April 2017. "AUA2016 Annual Meeting". ...
Percutaneous pulmonary valve implantation. production of septal defect in heart. enlargement of existing septal defect Atrial ... Heart pacemakers or valves may be inserted. Many other types of prostheses are used. ... creation of septal defect in heart Blalock-Hanlon procedure. shunt from heart chamber to blood vessel. atrium to pulmonary ... Surgery and other procedures involving the heart (ICD-9-CM V3 35-37+89.4+99.6, ICD-10-PCS 02) ...
The internal nasal valve comprises the area bounded by the upper lateral-cartilage, the septum, the nasal floor, and the ... For augmenting the nasal dorsum, autologous cartilage and bone grafts are preferred to (artificial) nose prostheses, because of ... The Surgery of Defects by Implantations, 1597), a technico-procedural manual for the surgical repair and reconstruction of ... Heart-lung transplant. Chest wall, pleura,. mediastinum,. and diaphragm. pleura/pleural cavity. Thoracentesis. Pleurodesis. ...
... valvular heart disease, angina pectoris, and atherosclerosis. Examples include the artificial heart, artificial heart valve, ... Simmons M, Montague D (2008). "Penile prosthesis implantation: past, present, and future". International Journal of Impotence ... and artificial heart valves, such as the Bjork-Shiley valve, all of which have caused FDA intervention. The consequences of ... Thus, heart valve failure is likely to threaten the life of the individual, while breast implant or hip joint failure is less ...
At left and right heart catheterisation, the pulmonary wedge pressure (PCW) showed cyclical variation, rising to a crescendo ... Intermittent opening of a mitral valve tilting disc prosthesis 23 years after implantation caused by circumferential pannus ... Intermittent opening of a mitral valve tilting disc prosthesis 23 years after implantation caused by circumferential pannus ... Mitral valve (MV) replacement with a 29 mm Bjork-Shiley tilting disc prosthesis had been performed 23 years earlier. ...
"Heart Valve Prosthesis Implantation" by people in this website by year, and whether "Heart Valve Prosthesis Implantation" was a ... Heart Valve Prosthesis Implantation*Heart Valve Prosthesis Implantation. *Implantation, Heart Valve Prosthesis ... Heart Valve Prosthesis Implantation [E04.100.376.485]. *Prosthesis Implantation [E04.650]. *Heart Valve Prosthesis Implantation ... "Heart Valve Prosthesis Implantation" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, ...
Heart valve prosthesis implantation. Amosov National Institute of Cardiovascular Surgery.. Lena Gulenko ...
Heart Valve Prosthesis Implantation. *Male. *Models, Animal. *Papio. *Pulmonary Artery. *Pulmonary Artery: surgery ... In the evaluation of pulmonary artery tissue engineered heart valves (TEHVs), pediatric CPB methods are adapted to accommodate ... Bioprosthetic valves or TEHVs were implanted as pulmonary replacements in 20 baboons: weight = 27.5 +/- 5.6 kg, height = 73 ... Surviving animals had normally functioning replacement valves and ventricles. Baboon CPB requires modifications to include high ...
Heart Valve Prosthesis Implantation. Additional relevant MeSH terms: Coronary Artery Disease. Myocardial Ischemia. Coronary ... To compare renal function (51Cr-EDTA clearance) 48 hours post open-heart surgery (coronary bypass or valve surgery) in patients ... or mitral valve vitriuim that are accepted for coronary artery bypass surgery and/or valve replacement surgery. ... evaluated by 51Cr-EDTA clearance between 24 hours pre open-heart surgery and 48 hours post open-heart surgery. Sample size is ...
Aortic Valve Disease Heart Valve Prosthesis Implantation Anticoagulants Drug: Rivaroxaban Phase 2 ... Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. (CATHAR). The safety ... Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206-14. doi: 10.1056/ ... is feasible and safe for prevention of major complications in patients undergoing a mechanical aortic heart valve replace-ment. ...
All mechanical heart valves are thrombogenic, and are associated with thromboembolic complications becomes ineffective. when ... Heart Valve Prosthesis / adverse effects*. Heart Valve Prosthesis Implantation. Humans. Mitral Valve* / surgery. Pregnancy. ... Title: The Journal of heart valve disease Volume: 9 ISSN: 0966-8519 ISO Abbreviation: J. Heart Valve Dis. Publication Date: ... To date, few reports are available of LMWH as sole anticoagulant in patients with mechanical heart valves. We report a case of ...
This research compares the late fate of these two valve types after valve re-replacement for structural val ... after valve re-replacement for bioprostheses is not well-documented. ... Heart Valve Prosthesis* / adverse effects, classification. Heart Valve Prosthesis Implantation*. Humans. Middle Aged. ... What prosthesis should be used at valve re-replacement after structural valve deterioration of a bioprosthesis?. ...
The prosthesis comprises a self expandable wire support structure surrounded by a flexible tubular membrane. A delivery ... Disclosed is a tubular endoluminal vascular prosthesis, useful in treating, for example, an abdominal aortic aneurysm. ... Method for direct implantation of a heart valve prosthesis. US9498363. 15 Mar 2013. 22 Nov 2016. Trivascular, Inc.. Delivery ... Method for direct implantation of a heart valve prosthesis. EP2520320A1. 30 Jun 2009. 7 Nov 2012. Endologix, Inc.. Catheter ...
... wherein the first anchor instrument defines a jaw space and is configured to deploy a staple prosthesis into a portion of a ... into a second tissue structure which is coupled to the staple prosthesis by a tensile member, such as a suture. ... and kits are described for addressing cardiac valve repair. A system for deploying a tensile member between two tissue ... Aortic heart valve prosthesis implantation tool. US6740107 *. 19 Dic 2001. 25 May 2004. Trimedyne, Inc.. Device for treatment ...
Aortic Valve Stenosis* / surgery * Disease Progression * Female * Follow-Up Studies * Heart Valve Prosthesis Implantation* ... Of the patients with moderately or severely calcified aortic valves whose aortic-jet velocity increased by 0.3 m per second or ... Event-free survival, with the end point defined as death (8 patients) or valve replacement necessitated by the development of ... Background: Whether to perform valve replacement in patients with asymptomatic but severe aortic stenosis is controversial. ...
Method for direct implantation of a heart valve prosthesis. US20120200099 *. Apr 18, 2012. Aug 9, 2012. Sabic Innovative ... Method for direct implantation of a heart valve prosthesis. US9445784. Sep 22, 2005. Sep 20, 2016. Boston Scientific Scimed, ... Methods of valve delivery on a beating heart. US9730753. Jul 7, 2016. Aug 15, 2017. Ethicon Endo-Surgery, Llc. Articulation ... Transapical heart valve delivery system and method. US20070225641 *. Dec 27, 2006. Sep 27, 2007. Clint Schneider. Auto lock for ...
Transcatheter aortic valve implantation (TAVI) has become an accepted treatment option for patients with symptomatic severe ... aortic stenosis who are at high risk for traditional surgical aortic valve replacement. In particular, TAVI has been shown to ... Heart Valve Prosthesis * Heart Valve Prosthesis Implantation / methods* * Humans * Prosthesis Design * Risk Factors ... Transcatheter aortic valve implantation (TAVI) has become an accepted treatment option for patients with symptomatic severe ...
Heart valve prosthesis and sutureless implantation of a heart valve prosthesis. March, 2002. Gabbay. ... Presently, the only permanent treatment for congestive heart disease is heart transplantation, but heart transplant procedures ... FLEXIBLE HEART VALVE. May, 2002. Carpentier et al.. 20020055767. Over-the-wire interlock attachment/detachment mechanism. May, ... 5K illustrates the heart 242 with the cardiac device 34 installed and the deployment mechanism 36 removed from the heart 242. ...
A prosthesis is formed from a biocompatible material having one or more associated cell adhesion stimulating proteins. The ... The implantation of heart valve prostheses is of particular interest. In these embodiments, the orifice ring and/or one or more ... Prostheses of particular interest include mechanical heart valve prostheses. A bi-leaflet mechanical heart valve prosthesis 100 ... In addition to heart valve prostheses formed with rigid occluders, heart valve prostheses can be constructed from tissue or ...
Heart Valve Prosthesis Implantation * Coronary Artery Bypass (Heart Bypass) * Thoracic/Cardiothoracic Surgery ... arteries and your lymphatic system to ensure blood circulation in your heart and in brain is the best it can be. Theyre well- ...
Heart Valve Prosthesis Implantation * Minimally Invasive Surgical Procedures * Deep Vein Thrombosis * Diabetes Complications ... arteries and your lymphatic system to ensure blood circulation in your heart and in brain is the best it can be. Theyre well- ...
Heart Valve Prosthesis Implantation ... Myocardial Infarction; Coronary Artery Bypass; Aortic Valve ...
KEY WORDS: Aortic valve; Bioprosthesis; Heart valve prosthesis implantation. top of page ... The valve inside the conduit could be easily surgically extracted, leaving the conduit and coronary ostia intact.. CONCLUSIONS ... METHODS: We tested the handling and implantability of this new aortic valved conduit in 8 human cadaver hearts, as well as the ... BACKGROUND: Currently, the only commercial pre-assembled aortic valved conduits employ mechanical valves, requiring lifelong ...
Heart Valve Prosthesis Implantation. 4. 2016. 1414. 0.420. Why? Blood Vessel Prosthesis. 1. 2014. 977. 0.390. Why? ...
Aortic heart valve prosthesis implantation tool US20040073245A1 (en) * 2002-02-22. 2004-04-15. Refocus Group, Inc. System and ... Aortic heart valve prosthesis implantation tool US20040167540A1 (en) * 2001-05-18. 2004-08-26. Georg Gerten. Marking instrument ... Aortic heart valve prosthesis sizer and marker US20030195497A1 (en) * 1999-04-28. 2003-10-16. St. Jude Medical, Inc.. Aortic ... Aortic heart valve prosthesis sizer and marker US20060106408A1 (en) * 2001-02-23. 2006-05-18. Ras Holding Corp. Surgical blade ...
Keywords: Endocarditis, Patient Selection, Heart Valve Prosthesis Implantation, Stents, Consensus , Back to Listings ... What is the initial German multicenter experience with implantation of a JenaValve transcatheter heart valve (THV) for the ... Initial German Experience With Transapical Implantation of a Second-Generation Transcatheter Heart Valve for the Treatment of ... Initial German Experience With Transapical Implantation of a Second-Generation Transcatheter Heart Valve for the Treatment of ...
Device for the implantation and fixing of heart valve prostheses US6306156B1 (en) 2001-10-23. Meniscus repair anchor system ... Prosthesis fixation device and method US7815659B2 (en) * 2005-11-15. 2010-10-19. Ethicon Endo-Surgery, Inc.. Suture anchor ... Surgical fastener implantation device US6540754B2 (en) 2003-04-01. Apparatus and method for multiply folding and inserting an ... Wedge shaped suture anchor and method of implantation US7476226B2 (en) 2009-01-13. Tools and methods for creating cavities in ...
Keywords: Fluoroscopy, Credentialing, Learning Curve, Catheters, Heart Valve Prosthesis Implantation, Angioplasty, Radiation ... Transcatheter Aortic Valve Implantation: Assessing the Learning Curve. Dec 21, 2011 Share via: ... YOU ARE HERE: Home , Latest in Cardiology , Transcatheter Aortic Valve Implantation: Assessing the Learning Curve ... The authors assessed the outcome of the first 44 consecutive patients who underwent transcatheter aortic valve implantation as ...
... predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis ... Transcatheter heart valve implantation for failing surgical bioprostheses: technical considerations and evidence for valve-in- ... Valvular heart disease. Complications of transcatheter aortic valve implantation (TAVI): how to avoid and treat them. Helge ... Transcatheter aortic valve implantation: implications of multimodality imaging in patient selection, procedural guidance, and ...
A porcine trileaflet valve is mounted to the stent. When the heart valve prosthesis is as implanted into the heart, the threads ... heart valve prosthesis is disclosed which has a biocompatible plastic sewing ring adapted to be surgically implanted into the ... mitral, aortic or tricuspid annulus of the human heart. The sewing ring has internal square threads and a biocompatible fabric ... Thus, at least sometime after the implantation of the heart valve prosthesis of the present invention, the patient (not shown) ...
Predictors and outcomes of heart failure after transcatheter aortic valve implantation using a self-expanding prosthesis. ... Sheathless transaxillary transcatheter aortic valve implantation using the Portico valve system. Initial experience of a real- ... Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure ... "Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure ...
In addition, the present invention is novel methods for surgically treating heart valves. ... The medical devices may be used individually, or in combination to supplement damaged valves, replace damaged valves, or ... improve damaged valves function. The medical devices include leaflet retainers, a neo-annulus, neo-leaflet, and a framework. ... The present invention is a group of medical devices designed to improve heart valve function. ...
Risk factors for pacemaker implantation following aortic valve replacement: a single centre experience. Heart. 2003;89:901-904. ... disorders and permanent pacemaker implantation after percutaneous aortic valve implantation with the CoreValve prosthesis. Am ... transcatheter aortic valve implantation. Introduction. Transcatheter aortic valve implantation (TAVI) is a relatively new, less ... Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation. 2009;119:3009-3016. ...
Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage ... Transcatheter valve implantation for deteriorated bioprostheses can be performed as valve-in-valve procedures. This may be ... Transseptal implantation of a transcatheter heart valve in a mitral annuloplasty ring to treat mitral repair failure. Circ ... Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case ...
  • Transcatheter aortic valve implantation (TAVI) has become an accepted treatment option for patients with symptomatic severe aortic stenosis who are at high risk for traditional surgical aortic valve replacement. (nih.gov)
  • In particular, TAVI has been shown to reduce mortality in a randomized comparison with medical treatment and to be non-inferior to surgical aortic valve replacement in 'high-risk operable' patients. (nih.gov)
  • From its early stages it became apparent that TAVI has tremendous potential and thus considerable efforts were made to design new devices and advance valve technology in order to improve outcomes and increase TAVI applications in complex anatomies and in patients with multiple co-morbidities. (nih.gov)
  • In this review, we present the advances in transcatheter aortic valve technology and discuss the current evidence on the new-generation TAVI devices. (nih.gov)
  • The aim of the present study was to investigate whether BNP also predicts the outcomes after transcatheter aortic valve implantation (TAVI). (biomedsearch.com)
  • Transcatheter aortic valve implantation (TAVI) with a JenaValve for the treatment of severe aortic regurgitation was performed in 31 patients (ages 73.8 ± 9.1 years) in nine German centers. (acc.org)
  • In the remaining patients, a significant improvement in New York Heart Association class was observed and persisted up to 6 months after TAVI. (acc.org)
  • What is the learning curve for transfemoral transcatheter aortic valve implantation (TAVI)? (acc.org)
  • Transcatheter aortic valve implantation (TAVI), a technique in which a bioprosthetic valve is inserted via a catheter and implanted within the diseased native aortic valve, is a new therapeutic modality for treatment of older patients with severe symptomatic aortic stenosis and other comorbidities, who have an inherently high surgical risk. (bmj.com)
  • while also investigating important complications and limitations of the procedure and evaluating how new valves are being designed and clinically evaluated, with the ultimate goal of reducing potential complications and expanding the use of TAVI to lower-risk patient cohorts. (bmj.com)
  • Transcatheter aortic valve implantation (TAVI), a technique in which a bioprosthetic valve is inserted via a catheter and implanted within the diseased native aortic valve, was first implanted by Andersen in 1993 in a closed chest experimental pig model. (bmj.com)
  • 9 It was a true 'resurrection' for Cribier and his whole team performing the first TAVI in an inoperable patient in 2002 10 , 11 using a transeptal antegrade approach and balloon-expandable aortic calve prosthesis, while at the same time in the USA, animal studies were being carried out to develop a transapical method of implantation. (bmj.com)
  • Since 2012, TAVI has been performed in more than 50 000 patients worldwide and a number of different aortic prostheses have since been developed. (bmj.com)
  • Objectives Our aim was to assess the safety and feasibility of the retrograde trans-subclavian approach to transcatheter aortic valve implantation (TAVI) in selected high-risk patients with aortic stenosis (AS) and severe peripheral vasculopathy. (onlinejacc.org)
  • Methods From among those patients in our department between May 2007 and December 2008, who were refused surgical aortic valve replacement because of high surgical risk and were ineligible for transfemoral percutaneous aortic valve replacement, we scheduled 3 for TAVI by the subclavian approach. (onlinejacc.org)
  • Conclusions TAVI by subclavian retrograde approach seems safe and feasible in inoperable/high-risk patients with AS and peripheral vasculopathy, who are neither eligible for surgical valve replacement nor transfemoral percutaneous aortic valve implantation. (onlinejacc.org)
  • Although first-generation devices for transcatheter aortic valve implantation (TAVI) have achieved favorable results in terms of clinical outcomes and valve performance, complications such as valve malpositioning, paravalvular leak, and conduction disturbances requiring permanent pacemaker implantation have emerged as important limitations of this procedure. (springer.com)
  • Partially offsetting these negative effects, the Abbott Structural Heart Portico™ TAVI device is fully re-sheathable, repositionable, and retrievable until deployed. (springer.com)
  • The Abbott Structural Heart Portico™ TAVI system provides a safe and effective treatment for patients with severe, symptomatic aortic stenosis who are considered to be at high or extreme risk for surgical aortic valve replacement. (springer.com)
  • The observed rates of early mortality as well as of disabling stroke are comparable with those reported from first- and second-generation TAVI systems, and 30-day mortality approaches the low procedural mortality rates reported for third-generation aortic valves implanted via transfemoral access. (springer.com)
  • Objectives This study sought to evaluate, through a systematic review of the published data, the main baseline characteristics, management, and clinical outcomes of patients suffering coronary obstruction as a complication of transcatheter aortic valve implantation (TAVI). (onlinejacc.org)
  • Conclusions Reported cases of coronary obstruction after TAVI occurred more frequently in women, in patients receiving a balloon-expandable valve, and the LCA was the most commonly involved artery. (onlinejacc.org)
  • Transcatheter aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic valve replacement in those patients considered at very high or prohibitive risk for surgery ( 1 ). (onlinejacc.org)
  • Despite its more widespread adoption as a treatment option and the increasing experience of the centers, TAVI is still associated with complications, such as vascular/bleeding and cerebrovascular events, conduction abnormalities requiring permanent pacemaker implantation, and significant residual aortic regurgitation ( 1 ). (onlinejacc.org)
  • Transcatheter aortic valve implantation (TAVI) has had a major impact on both morbidity and mortality in high-risk and inoperable patients with severe aortic stenosis. (bmj.com)
  • Objectives The aim of the current Valve Academic Research Consortium (VARC)-2 initiative was to revisit the selection and definitions of transcatheter aortic valve implantation (TAVI) clinical endpoints to make them more suitable to the present and future needs of clinical trials. (onlinejacc.org)
  • Conclusions This VARC-2 document has provided further standardization of endpoint definitions for studies evaluating the use of TAVI, which will lead to improved comparability and interpretability of the study results, supplying an increasingly growing body of evidence with respect to TAVI and/or surgical aortic valve replacement. (onlinejacc.org)
  • Due to a very high estimated surgical risk the patient underwent PTCA of the main left trunk followed, a week later, by trans catheter implantation of an aortic valve (TAVI). (bvsalud.org)
  • Vanwege haar taak als toezichthouder heeft de Inspectie voor Gezondheidszorg en Jeugd (IGJ) het RIVM gevraagd de technische documentatie te beoordelen van vijf TAVI-producten. (rivm.nl)
  • The first of these 'transcatheter aortic valve implantation devices' (TAVI) became available in Europe in 2007. (rivm.nl)
  • VD-AR after THV implantation provides a quantitative assessment of post-TAVI regurgitation and can help in the decision-making process on performing BPD and in determining its efficacy. (sanarmed.com)
  • A porcine trileaflet valve is mounted to the stent. (google.com)
  • When the heart valve prosthesis is as implanted into the heart, the threads of the sewing ring and of the stent support ring interlock, and there are no plastic or metal surfaces, uncovered by biocompatible fabric, to be exposed to blood flow. (google.com)
  • 2. The heart valve prosthesis of claim 1 wherein the stent is a tubular member comprising a substantially solid plate of biocompatible metal. (google.com)
  • 3. The heart valve prosthesis of claim 2 wherein the stent includes a plurality of apertures adapted for receiving sutures for mounting the valve means to the stent. (google.com)
  • 4. The heart valve prosthesis of claim 3 wherein the solid plate of the stent comprises an elongated substantially flat plate which had been bent to meet at two opposite edges, said edges having been welded together with an overlying plate. (google.com)
  • 5. The heart valve prosthesis of claim 1 wherein the sewing ring and the stent support ring comprise thermoplastic material which can be formed by a molding process. (google.com)
  • 6. The heart valve prosthesis of claim 5 wherein the first and second cloth are embedded into the sewing ring and stent support ring, respectively, by a plastic molding process. (google.com)
  • Stent-based transcatheter valve replacement now offers patients a less invasive alternative with potentially reduced risks, which may be particularly beneficial for elderly, high-risk patients. (cmaj.ca)
  • The design and construction of the device itself consists of xenogenic pericardial cusps mounted within an expandable stent that relies upon the forces of radial traction to seat the prosthesis tightly within the native aortic annulus. (cmaj.ca)
  • B) The self-expanding CoreValve (Medtronic) transcatheter prosthesis stent for aortic valve implantation. (cmaj.ca)
  • The Edwards SAPIEN valve consists of trileaflet bovine-pericardium valve mounted on a balloon-expandable stainless steel stent, and is available in four sizes (20, 23, 26 and 29 mm). (bmj.com)
  • Transapical VinV implantation of a pericardial xenograft fixed within a 23-mm stainless steel, balloon expandable stent (Cribier Edwards, Edwards Lifesciences, Irvine, California) was then performed under fluoroscopic and echocardiographic visualization on the beating heart with ventricular unloading via cardiopulmonary bypass and rapid ventricular pacing. (onlinejacc.org)
  • The radiopaque marking within the stent of the conventional aortic or mitral xenograft allowed for optimal positioning of the stent-delivered valve. (onlinejacc.org)
  • Conclusions The VinV concept is promising for minimally invasive beating heart repeat aortic or mitral valve replacement, using a stent-fixed sutureless prosthesis. (onlinejacc.org)
  • The goal of this study was to evaluate the feasibility of transcatheter implantation of a sutureless stent-fixed xenograft into a conventional bioprosthesis (valve-in-a-valve [VinV]) on the beating heart using a minimally invasive transapical approach in an acute experimental model. (onlinejacc.org)
  • An 18-mm bovine valve was mounted in the central part of the stent, and a polytetrafluoroethylene membrane was sutured onto the ventricular disk. (ucl.ac.uk)
  • A disk-based nitinol stent is needed to allow valve implantation in the atrioventricular position. (ucl.ac.uk)
  • The present disclosure relates to a delivery catheter and the stepwise release of a stent from the catheter into the vasculature of a patient, as well as a loading device for a transcatheter heart valve (THV) prosthesis. (sumobrain.com)
  • A method for sequential deployment of a stent or prosthesis wherein a 1st sleeve (11) of the catheter is moved followed by the movement of a stent holder (15) resulting in the liberation and directed deployment of the stent or prosthesis. (sumobrain.com)
  • 2019 AATS/ACC/ASE/SCAI/STS expert consensus systems of care document: A proposal to optimize care for patients with valvular heart disease: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. (rush.edu)
  • During follow-up, two patients underwent valvular reinterventions (surgical aortic valve replacement for endocarditis, valve-in-valve implantation for increasing paravalvular regurgitation). (acc.org)
  • Most frequently this has manifested as a heart team to manage complex valvular heart disease as it pertains to TAVR, but the concept has also been applied to other cardiovascular conditions such as acute aortic syndromes or arrhythmias. (ahajournals.org)
  • Traditional surgical valve replacement has been the mainstay in the treatment of severe aortic valvular disease, and in the absence of serious comorbidities it is associated with low operative mortality. (bmj.com)
  • While re-endothelialization of decellularized heart valves has already been successfully implemented, interstitial repopulation still remains an unaccomplished objective although it is essential for valvular functionality and regeneration potential. (ovid.com)
  • A novel 3D heart valve model has been developed to investigate the cell behaviour of valvular interstitial cells (VIC) in their physiological environment and to evaluate the potential of in vitro repopulation of acellular heart valves. (ovid.com)
  • The etiology of valvular heart disease and management of congenital heart disease in young women continues to change. (biomedcentral.com)
  • Replacement of diseased valves with prosthetic heart valves reduces the morbidity and mortality associated with native valvular disease, but it comes at the expense of risking complications related to the implanted prosthetic device. (medscape.com)
  • La disfunción de las bioprótesis quirúrgicas frecuentemente ocurre en pacientes añosos, con severas comorbilidades, lo que implica un riesgo elevado frente a una nueva cirugía valvular. (bvsalud.org)
  • ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. (springer.com)
  • Guidelines on the management of valvular heart disease. (springer.com)
  • Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. (springer.com)
  • The reoperation rate was 12.1% in the bioprosthetic valve group at 15 years and 6.9% in the mechanical valve group, while major bleeding occurred in 6.6% of bioprosthesis patients and in 13.0% of the mechanical-valve group. (medscape.com)
  • Transcatheter valve implantation within a surgical bioprosthesis, so-called valve in valve procedure (VIV), has been developed as new treatment option for this situation. (bvsalud.org)
  • After institution of CardioPulmonary Bypass (CPB) the aortic cross clamp is applied to the ascending aorta, endoluminally in mitral & tricuspid valve surgery, using the endoballoon (Edwards Lifesciences, Irvine, CA, USA) or externally in aortic valve surgery ( 11 ). (escardio.org)
  • Retrospective analysis of medical records of 37 patients undergoing aortic valve replacement by sternotomy or minimally invasive approach, with emphasis on the comparison of time of cardiopulmonary bypass and aortic clamping, volume of surgical bleeding, time of mechanical ventilation, need for blood transfusion, incidence of atrial fibrillation, length of stay in intensive care unit, time of hospital discharge, short-term mortality and presence of surgical wound infection. (bjcvs.org)
  • The VinV implantation is a promising new technique for minimally invasive beating heart repeat aortic or mitral valve replacement. (onlinejacc.org)
  • PURPOSE: The incidence of prosthesis-patient mismatch (PPM) after mitral valve replacement (MVR) has been reported to vary. (bvsalud.org)
  • The data from this large study of adults having isolated aortic valve replacement for aortic stenosis (with or without associated aortic regurgitation) and without associated mitral stenosis or mitral valve replacement strongly suggest that an underlying congenitally malformed valve, at least in men, is more common than a tricuspid aortic valve. (nih.gov)
  • We performed a mitral valve replacement combined with a Ravitch procedure in a young female with previous left pneumonectomy and pectus excavatum. (bjcvs.org)
  • These studies open new perspectives into tricuspid as well as mitral valve replacement. (ucl.ac.uk)
  • In the evaluation of pulmonary artery tissue engineered heart valves (TEHVs), pediatric CPB methods are adapted to accommodate the animals' unique physiology enabling survival up to 6 months until elective sacrifice. (mendeley.com)
  • Methods, devices, and kits are described for addressing cardiac valve repair. (google.es)
  • METHODS: We tested the handling and implantability of this new aortic valved conduit in 8 human cadaver hearts, as well as the valve removal potential without detaching the coronary ostia. (minervamedica.it)
  • In addition, the present invention is novel methods for surgically treating heart valves. (google.ca)
  • Methods Conventional Carpentier Edwards porcine aortic (n = 5) and mitral (n = 2) valve prostheses were implanted in 7 pigs. (onlinejacc.org)
  • METHODS: Between 1991 and 2004, 64 consecutive patients younger than 3 months old underwent open surgical commissurotomy because of aortic valve stenosis. (lu.se)
  • The present disclosure relates to the field of medical devices, in particular to a prosthesis which is transplanted into an individual in need thereof in order to reestablish proper body functions by way of minimally invasive methods and means applicable therefor. (sumobrain.com)
  • Examples of prostheses that are placed by way of minimally invasive methods are stents and heart valves like aortic and mitral heart valves. (sumobrain.com)
  • ABSTRACT Aortic valve replacement via open heart surgery, although still the standard treatment for severe symptomatic aortic valve stenosis, is not an option for many patients with severe symptoms, and these patients are often left with suboptimal strategies such as medical management or balloon valvuloplasty. (mdedge.com)
  • A) The balloon-expandable SAPIEN (Edwards Lifesciences) transcatheter prosthesis for aortic valve implantation. (cmaj.ca)
  • C) The balloon-expandable Melody (Medtronic) prosthesis for pulmonic valve implantation in congenital heart disease. (cmaj.ca)
  • Currently available devices in the United States include the self-expandable Evolut R and Evolut PRO valves, the balloon-expandable Sapien3 and Sapien 3 Ultra valves, and the mechanically-expandable Lotus Edge valve. (medscape.com)
  • Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. (springer.com)
  • Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement. (springer.com)
  • TAVR is a minimally invasive, catheter-based procedure to replace the function of the aortic valve. (medscape.com)
  • Objectives This study sought to evaluate the feasibility of minimally invasive transapical repeat valve-in-a-valve (VinV) implantation. (onlinejacc.org)
  • Moreover, recent years have witnessed a renewed interest in minimally invasive aortic valve replacement (miAVR). (bmj.com)
  • In the paper, the cross-disciplinary team successfully implanted JetValves in sheep using a minimally invasive technique and demonstrated that the valves functioned properly in the circulation and regenerated new tissue. (nanowerk.com)
  • In addition, the new heart valve would be compatible with minimally invasive procedures to serve both pediatric and adult patients. (nanowerk.com)
  • Performed since the mid 1990's, minimally invasive heart valve surgery avoids complete sternotomy, for reduced trauma and pain in the early postoperative period. (escardio.org)
  • Compared to the conventional full median sternotomy surgical approach, standardised techniques of minimally invasive heart surgery have shown growing evidence of similar or better results. (escardio.org)
  • Minimally Invasive Heart valve Sugery (MIHVS) is commonly performed through a right mini thoracotomy ( 1 2 , 3 ), a parasternal incision - adjacent to the sternum - or a hemi-sternotomy. (escardio.org)
  • To compare the results of aortic valve replacement with access by sternotomy or minimally invasive approach. (bjcvs.org)
  • A 38-year-old man with recurrent tricuspid endocarditis underwent redo tricuspid valve replacement by means of a minimally invasive right thoracotomy with a 32-mm St. Jude bioprosthetic valve. (elsevier.com)
  • In collaboration the two teams successfully implanted JetValves in sheep using a minimally invasive technique and demonstrated that the valves functioned properly in the circulation and regenerated new tissue. (longecity.org)
  • The present disclosure relates to a delivery system, a catheter system and a method for the minimally invasive application of prostheses to individuals in need thereof and a method and device for loading a prosthesis onto a catheter system and/or a delivery system. (sumobrain.com)
  • He has a particular surgical and academic interest in arterial revascularisation, heart valve and aortic root repair, minimally invasive heart valve surgery, thoracic aortic surgery, repeat and complex cardiac operations. (hcahealthcare.co.uk)
  • To determine if rivaroxaban (Xarelto) is feasible and safe for prevention of major complications in patients undergoing a mechanical aortic heart valve replace-ment. (clinicaltrials.gov)
  • This is a Prospective, Open-label Phase 2 Pilot Study With Independent Evaluation of All Outcomes and a Historical Control Group to Determine if Rivaroxaban (Xarelto) is Feasible and Safe for Prevention of Major Complications in Patients Undergoing a Mechanical Aortic Heart Valve Replacement. (clinicaltrials.gov)
  • All mechanical heart valves are thrombogenic, and are associated with thromboembolic complications becomes ineffective. (biomedsearch.com)
  • However, due to surgical risks and early and late complications of prosthetic heart valves, the ideal time for surgery is often considered controversial [2] . (bjcvs.org)
  • Owing to these changes, surgical access to heart and great vessels becomes challenging, and there is increased risk of postoperative pulmonary complications. (bjcvs.org)
  • Echocardiography plays an important role in the percutaneous procedure of transcatheter aortic valve replacement (TAVR), starting with pre-implant screening, choosing the correct size of the valve device, in the case of complications during implantation, and in post-implant and follow-up assessment. (springer.com)
  • Heys R, Angelini G, Caputo M, Culliford L, Pufulete M, Reeves BC, Rogers CA, Stoica S, Parry A. 'Off pump' self-expanding injectable tissue valves (IPVR) versus 'on pump' conventional tissue valves (PVR) for replacement of the pulmonary valve: trial protocol for a randomised controlled trial (InVITe trial). (rush.edu)
  • Should Tricuspid Annuloplasty be Performed With Pulmonary Valve Replac" by Mustafa Kurkluoglu, Anitha S. John et al. (gwu.edu)
  • Should Tricuspid Annuloplasty be Performed With Pulmonary Valve Replacement for Pulmonary Regurgitation in Repaired Tetralogy of Fallot? (gwu.edu)
  • This study sought to investigate the impact of tricuspid regurgitation (TR) on right ventricular function after percutaneous pulmonary valve implantation (PPVI). (unboundmedicine.com)
  • Cardiovascular interventions JO - JACC Cardiovasc Interv VL - 10 IS - 7 N2 - OBJECTIVES: This study sought to investigate the impact of tricuspid regurgitation (TR) on right ventricular function after percutaneous pulmonary valve implantation (PPVI). (unboundmedicine.com)
  • Generally, a predicted mortality risk of greater than 15% with conventional aortic valve replacement is considered high risk. (cmaj.ca)
  • Calcific aortic valve disease is relatively common in the high-income countries, affecting between 4% and 5% of adults above the age of 75 years, and unless corrected, it carries significant morbidity and mortality. (bmj.com)
  • Do hospitals with low mortality rates in coronary artery bypass also perform well in valve replacement? (mdedge.com)
  • Combined heart surgery and lung resection can be performed without increased mortality and/or morbidity. (medscimonit.com)
  • Advances in surgical technique, prosthetic heart valve design, and anticoagulation have contributed to an overall improvement in morbidity and mortality in women with heart valve prostheses as well as increased feasibility of pregnancy. (biomedcentral.com)
  • CONCLUSIONS: Surgical commissurotomy for aortic valve stenosis during the first 3 months of life can be done with low mortality and morbidity. (lu.se)
  • Even when promptly recognized and treated, acute prosthetic valve failure is associated with a high mortality rate. (medscape.com)
  • In propensity-matched comparisons, actuarial 15-year mortality rates were 60.6% with the bioprosthetic aortic valve and 62.1% with the mechanical valve. (medscape.com)
  • In adults with severe, symptomatic aortic stenosis, 2-year mortality is approximately 50% (2) , and open surgical aortic valve replacement (SAVR) is the only treatment that has been shown to improve symptoms, functional status, and survival (3) . (annals.org)
  • Patients with low body mass index (/m(2) ) undergoing transcatheter aortic valve replacement have higher short- and long-term mortality Low BMI is an important tool to consider in patient screening and prognostication Prospective study is needed to accurately assess the effects of BMI in TAVR patients, to prove or refute the obesity paradox. (henryford.com)
  • In last few years sutureless aortic valve bioprostheses have been developed to facilitate surgical AVR, reduce aortic cross-clamping and CPB time and curtail risk of mortality and morbidity. (rbccv.org)
  • Balloon post-dilatation (BPD) is often needed for optimizing transcatheter heart valve (THV) implantation, since paravalvular leak (PVL) after transcatheter aortic valve implantation is associated with poor outcome and mortality. (sanarmed.com)
  • The principles of this technology are aimed at relieving the stenosis of the native valve and creating a functioning valve that can be delivered via a catheter-based system on the beating heart, without the need for a heart-lung machine or sternotomy. (cmaj.ca)
  • 12 This became feasible following development of a catheter that could be flexed to get around the aortic arch and across the aortic valve. (bmj.com)
  • A thin, flexible catheter with the heart valve is guided through the incision into the artery and to the diseased valve. (medscape.com)
  • Percutaneous heart valve replacement (PHVR) is an emerging, catheter-based technology that allows for implantation of a prosthetic valve without open heart surgery. (annals.org)
  • In recent years, new techniques have been developed with less impact on patients, for example the use of a catheter to insert the prosthesis. (rivm.nl)
  • Anatomy of the aortic valvar complex and its implications for trans-catheter implantation of the aortic valve. (springer.com)
  • Evaluation of aortic root for definition of prosthesis size by magnetic resonance imaging and cardiac computed tomography: implications for trans-catheter aortic valve implantation. (springer.com)
  • Heart Valve Prosthesis Implantation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (rush.edu)
  • A tight seal within the cusps of the crushed native aortic valve and the surrounding annulus is necessary to prevent paravalvular leakage. (cmaj.ca)
  • Results Prosthetic valves were successfully implanted in all 3 cases, leading to a fall in transvalvular gradient without significant paravalvular regurgitation. (onlinejacc.org)
  • All valves were firmly positioned, and there were neither migration nor paravalvular or transvalvular leaks. (onlinejacc.org)
  • Prior reports from the CoreValve U.S. Pivotal Trial (Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement) suggested that patients surviving to 1 year experienced significant regression of paravalvular regurgitation (PVAR) (3) , a surprising finding without a clear etiology. (onlinejacc.org)
  • Van Belle and colleagues hypothesized that transcatheter aortic valve replacement (TAVR) would correct this process, but that significant residual paravalvular leak (PVL) following TAVR would abrogate this corrective effect. (bmj.com)
  • Four valves were explanted due to significant paravalvular leak after surgery. (rbccv.org)
  • Determinants of significant paravalvular regurgitation after transcatheter aortic valve: implantation impact of device and annulus discongruence. (springer.com)
  • Predicting paravalvular regurgitation following transcatheter valve replacement: utility of a novel method for three-dimensional echocardiographic measurements of the aortic annulus. (springer.com)
  • Prosthesis/annulus discongruence assessed by three-dimensional transesophageal echocardiography: a predictor of significant paravalvular aortic regurgitation after transcatheter aortic valve implantation. (springer.com)
  • On transesophageal echocardiography (TEE), a severe paravalvular leakage of the prosthetic mitral valve was demonstrated due to an almost complete dehiscence. (asm.org)
  • Mitral valve (MV) replacement with a 29 mm Bjork-Shiley tilting disc prosthesis had been performed 23 years earlier. (bmj.com)
  • Surviving animals had normally functioning replacement valves and ventricles. (mendeley.com)
  • Patients with significant coronary stenosi(e)s (≥ 75% coronary artery lumen surface stenosi(e)s and / or aortic- or mitral valve vitriuim that are accepted for coronary artery bypass surgery and/or valve replacement surgery. (clinicaltrials.gov)
  • Comparison of Antithrombotic Treatments After Aortic Valve Replacement. (clinicaltrials.gov)
  • To identify the value of molecular markers suitable for monitoring of anticoagulation effectiveness of rivaroxaban and its correlation with transcranial Doppler emboli count in patients undergoing a mechanical aortic heart valve replacement. (clinicaltrials.gov)
  • Whether to perform valve replacement in patients with asymptomatic but severe aortic stenosis is controversial. (nih.gov)
  • Event-free survival, with the end point defined as death (8 patients) or valve replacement necessitated by the development of symptoms (59 patients), was 67+/-5 percent at one year, 56+/-5 percent at two years, and 33+/-5 percent at four years. (nih.gov)
  • These patients should be considered for early valve replacement rather than have surgery delayed until symptoms develop. (nih.gov)
  • B-type natriuretic peptide (BNP) has been shown to predict outcomes after conventional aortic valve replacement. (biomedsearch.com)
  • Such hybrid procedures include transcatheter aortic valve replacement (TAVR), endovascular thoracic (TEVAR) or abdominal (EVAR) aortic repair, and combined percutaneous coronary intervention (PCI) with structural heart intervention. (ahajournals.org)
  • Valve replacement remains the only definitive therapy for patients with severe aortic stenosis. (cmaj.ca)
  • Innovative techniques and emerging technologies have been focused on such high-risk patients, enabling less invasive valve replacement to be performed without the need for sternotomy, use of heart-lung bypass machines or even stopping the heart. (cmaj.ca)
  • Our review focuses on the clinical results and future possibilities for transcatheter valve replacement therapy. (cmaj.ca)
  • CE mark) approval: the SAPIEN (Edwards Lifesciences) and CoreValve (Medtronic) devices, which are for aortic valve replacement, and the Melody (Medtronic) device which is for pulmonic valve replacement in congenital heart disease ( Figure 1 ). (cmaj.ca)
  • Initially, patients were selected for transcatheter aortic valve replacement on a compassionate basis only, such that the valves were applied to moribund patients without traditional surgical options. (cmaj.ca)
  • Severe calcific aortic stenosis is relatively common, and unless treated with valve replacement it carries an adverse prognosis. (bmj.com)
  • Until relatively recently, surgical aortic valve replacement has been the standard of care in adults with severe symptomatic aortic stenosis . (medscape.com)
  • However, the risks associated with surgical aortic valve replacement are increased in elderly patients and those with concomitant severe systolic heart failure or coronary artery disease, as well as in patients with comorbidities such as cerebrovascular and peripheral arterial disease, chronic kidney disease, and chronic respiratory dysfunction. (medscape.com)
  • Transcatheter aortic valve replacement (TAVR) was developed as an alternative to the surgical approach in this high-risk and inoperable population. (medscape.com)
  • Indicated for patients at intermediate or greater risk for open heart surgery, TAVR may be an excellent option for certain patients because the prevalence of aortic stenosis and comorbidities may increase the risks associated with surgical aortic valve replacement (SAVR). (medscape.com)
  • No established indications or guidelines exist yet for transcatheter aortic valve replacement (TAVR) in the United States. (medscape.com)
  • To date, about one-third of patients affected by aortic stenosis are not considered for surgical valve replacement because of the high operative risk and because their prognosis is poor. (onlinejacc.org)
  • Technical and device issues are being refined, and percutaneous aortic valve replacement is showing promise in ongoing clinical trials. (mdedge.com)
  • Many patients with severe aortic valve stenosis are considered too high-risk for standard surgical valve replacement but may be candidates for percutaneous valve replacement. (mdedge.com)
  • The technology is still evolving, and the learning curve is substantial, yet cautious enthusiasm about percutaneous aortic valve replacement is justified. (mdedge.com)
  • Cribier A , Savin T , Saoudi N , Rocha P , Berland J , Letac B . Percutaneous transluminal valvuloplasty of acquired aortic stenosis in elderly patients: an alternative to valve replacement? (mdedge.com)
  • Three patients underwent aortic valve replacement with right upper lobectomy. (medscimonit.com)
  • Background Reoperative heart valve replacement for degenerated xenografts is associated with an increased surgical risk. (onlinejacc.org)
  • Heart valve replacement is routinely performed using xenografts in elderly patients, leading to good hemodynamic and functional outcome. (onlinejacc.org)
  • Transcatheter aortic valve replacement (TAVR) has recently been approved for use in patients who are at intermediate and low surgical risk. (bmj.com)
  • however, the advent of transcatheter aortic valve replacement (TAVR) has gained appreciable momentum, with a nearly ninefold increase in utilisation between 2012 and 2016. (bmj.com)
  • Transcatheter aortic valve replacement with the St. Jude Medical Portico™ valve: first-in-human experience. (springer.com)
  • Transcatheter aortic valve replacement with the Portico™ valve: one-year results of the early Canadian experience. (springer.com)
  • Transcatheter aortic valve replacement with new-generation devices: a systematic review and meta-analysis. (springer.com)
  • Transcatheter versus surgical aortic-valve replacement in high-risk patients. (springer.com)
  • Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system-30-day primary endpoint results from the REPRISE II study. (springer.com)
  • Instead they designed a caged ball device for the replacement of the mitral valve. (si.edu)
  • The science and practice of rigorous quantitative echocardiography has never been more important than in the era of transcatheter treatment of structural heart disease and specifically transcatheter aortic valve replacement (TAVR). (onlinejacc.org)
  • Median time to reoperation was 4.3 years (range, 0.2 to 11.3 years) and to aortic valve replacement (7 Ross and 1 homograft) was 6.9 years (range, 1.6 to 9.7 years). (lu.se)
  • The risk for early recurrent stenosis or regurgitation is low, and the need for aortic valve replacement can, in most cases, be delayed until the child is older. (lu.se)
  • Bioprosthetic valves (see the image below) used in heart valve replacement generally offer functional properties (eg, hemodynamics, resistance to thrombosis) that are more similar to those of native valves. (medscape.com)
  • In a retrospective cohort analysis of 4253 patients who underwent primary isolated aortic-valve replacement, 15-year survival and stroke rates were equivalent with bioprosthetic and mechanical valves. (medscape.com)
  • Use of transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) has grown rapidly over the last decade and the technology has correspondingly matured. (bmj.com)
  • Transcatheter aortic valve replacement (TAVR) is superior to medical therapy in inoperable patients with severe, symptomatic aortic stenosis (AS), and may be the preferred option in high-risk surgical patients. (bmj.com)
  • The comparative efficacy of TAVR and surgical aortic valve replacement (SAVR) in intermediate risk AS patients has been less well studied. (bmj.com)
  • The advent of transcatheter aortic valve replacement (TAVR) has afforded an alternative to surgical aortic valve replacement (SAVR) for high-risk or non-operative candidates for aortic valve surgery. (bmj.com)
  • In a paper published in Biomaterials ( 'JetValve: Rapid manufacturing of biohybrid scaffolds for biomimetic heart valve replacement' ), Andrew Capulli, Ph.D. and colleagues fabricated a valve-shaped nanofiber network that mimics the mechanical and chemical properties of the native valve extracellular matrix (ECM). (nanowerk.com)
  • In support of these translational efforts, the Wyss Institute for Biologically Inspired Engineering and the University of Zurich announced today a cross-institutional team effort to generate a functional heart valve replacement with the capacity for repair, regeneration, and growth. (nanowerk.com)
  • Surgical aortic valve replacement (SAVR) is the only treatment known to improve symptoms and survival in patients with severe, symptomatic aortic stenosis. (annals.org)
  • Surgical aortic valve replacement is the only proven effective treatment of aortic stenosis. (annals.org)
  • To date, little overlap exists between the patient populations who have received surgical versus percutaneous aortic valve replacement, and long-term outcomes associated with PHVR have rarely been reported. (annals.org)
  • http://my.webmd.com/content/asset/adam_surgery_valve_replacement (20 Oct. 2000). (123helpme.com)
  • Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, wi. (nih.gov)
  • AR patients showed a statistically significant decrease in absolute/indexed LVMM during follow up, but never achieved LV mass recovery compared to standard values or to values in patients undergoing aortic valve replacement for AS. (cdc.gov)
  • Transcatheter versus surgical aortic valve replacement episode payment" by Alexander A. Brescia, John D. Syrjamaki et al. (henryford.com)
  • Transcatheter versus surgical aortic valve replacement episode payments and relationship to case volume. (henryford.com)
  • BACKGROUND: Transcatheter aortic valve replacement (TAVR) has increased in volume as an alternative to surgical aortic valve replacement (SAVR). (henryford.com)
  • These data will be increasingly important to address value-based reimbursement in valve replacement surgery. (henryford.com)
  • The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement. (cdc.gov)
  • OBJECTIVE: Aortic stenosis (AS) patients are often severely symptomatic at the time of aortic valve replacement (AVR). (chalmers.se)
  • BACKGROUND: Aortic valve replacement (AVR) improves left ventricular (LV) systolic function in patients with chronic aortic regurgitation (AR). (yonsei.ac.kr)
  • The objective of this study is to determine predictors for normalization of impaired LV systolic function after valve replacement for chronic AR. (yonsei.ac.kr)
  • CONCLUSIONS: In patients who received a valve replacement for chronic AR, smaller indexed LV systolic and diastolic dimensions were associated with early restoration of LV systolic function. (yonsei.ac.kr)
  • Myocardial revascularization surgery was performed in 36 patients, replacement of the aortic valve in 5 patients, and replacement of the mitral valve in 5 patients. (bvsalud.org)
  • The aim of this retrospective study is to evaluate the safety and performance of the Perceval sutureless valve in patients undergoing aortic valve replacement. (rbccv.org)
  • From January 2014 to December 2016, 139 patients underwent sutureless aortic valve replacement. (rbccv.org)
  • Ninety-two patients underwent isolated aortic valve replacement (group A) with Perceval valve and 47 patients had combined procedures of aortic valve replacement and coronary artery bypass grafting (group B). The patients received a size S (n=23), M (n=39), L (n=42) or XL (n=35) prosthesis. (rbccv.org)
  • We herein describe the first-ever report of RCA injury related to tricuspid valve replacement surgery. (elsevier.com)
  • Morrissy, SJ, Atkins, BZ & Rogers, JH 2014, ' Iatrogenic right coronary artery stenosis resulting from surgical tricuspid valve replacement: Case report and review of the literature ', Catheterization and Cardiovascular Interventions , vol. 84, no. 7, pp. 1110-1114. (elsevier.com)
  • Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. (springer.com)
  • Aortic annular sizing for transcatheter aortic valve replacement using cross-sectional 3-dimensional transesophageal echocardiography. (springer.com)
  • Total arch replacement combined with stented elephant trunk implantation: a new "standard" therapy for type a dissection involving repair of the aortic arch? (labome.org)
  • Steps toward the percutaneous replacement of atrioventricular valves an experimental study. (ucl.ac.uk)
  • OBJECTIVES: The goal of this study was to develop a device for percutaneous replacement of the tricuspid valve in animals. (ucl.ac.uk)
  • BACKGROUND: Percutaneous valve replacement has recently been introduced, and early clinical experience has been reported. (ucl.ac.uk)
  • To date, this technique is limited to the replacement of pulmonary and aortic valves in selected patients. (ucl.ac.uk)
  • In all patients, wide debridement of abscess and aortic valve replacement with or without patch reconstruction of aortic root or annulus was performed. (yonsei.ac.kr)
  • A case of Heyde syndrome: resolution following aortic valve replacement. (unboundmedicine.com)
  • An 80-year-old woman with severe aortic stenosis was referred to our department for an aortic valve replacement. (unboundmedicine.com)
  • After aortic valve replacement her anemia was resolved. (unboundmedicine.com)
  • Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. (clinicaltrials.gov)
  • Ovine aortic heart valves were decellularized by detergent solutions and additionally treated with trypsin or laser perforation. (ovid.com)
  • The corresponding author of this article is a member of the research team which focuses on developing a bioresorbable aortic heart valve (HV) prosthesis. (springer.com)
  • A 'tissue valve type' heart valve prosthesis is disclosed which has a biocompatible plastic sewing ring adapted to be surgically implanted into the mitral, aortic or tricuspid annulus of the human heart. (google.com)
  • The main causes of AS are congenital stenosis, aortic valve calcification, bicuspid or tricuspid stenosis and degenerative rheumatic fever. (bjcvs.org)
  • Transthoracic echocardiogram revealed severe mitral regurgitation due to myxomatous mitral valve with bileaflet prolapse and chordal elongation, secondary pulmonary hypertension, and tricuspid regurgitation with a dilated right atrium. (bjcvs.org)
  • Iatrogenic injury to the right coronary artery (RCA) is a rare complication of tricuspid valve surgery. (elsevier.com)
  • The RCA runs in the atrioventricular groove and is susceptible to injury especially in the region of the posterior leaflet of the tricuspid valve, where the relationship of the tricuspid annulus to the RCA is most intimate. (elsevier.com)
  • CONCLUSIONS: Implantation of a semi-lunar valve in the tricuspid position is possible in ewes through a transcatheter approach. (ucl.ac.uk)
  • Propensity-matched analysis of outcomes after mitral valve surgery between trainees and consultants (institutional report). (rush.edu)
  • In conclusion, BNP is a strong predictor of 30-day outcomes after transcatheter aortic valve implantation, at both baseline and 24 hours after the procedure. (biomedsearch.com)
  • The objective of this systematic review will be to assess the outcomes of pregnancy in women with heart valve prostheses in contemporary populations. (biomedcentral.com)
  • With these changes in mind, understanding the outcomes of pregnancies in women who have heart valve prostheses in the contemporary setting is of increasing relevance. (biomedcentral.com)
  • The bicuspid aortic valve: adverse outcomes from infancy to old age. (nih.gov)
  • Quantitative assessment of PVL severity before and after BPD is mandatory to properly assess PVL, thus improving implantation results and outcomes. (sanarmed.com)
  • Of the patients with moderately or severely calcified aortic valves whose aortic-jet velocity increased by 0.3 m per second or more within one year, 79 percent underwent surgery or died within two years of the observed increase. (nih.gov)
  • The authors assessed the outcome of the first 44 consecutive patients who underwent transcatheter aortic valve implantation as part of the PARTNER (Placement of Aortic Transcatheter Valves) trial at a single institution between November 2008 and May 2011. (acc.org)
  • A retrospective study is presented of five male patients who underwent combined surgical treatment for heart and lung disease in a one-step procedure between November 2004 and November 2006. (medscimonit.com)
  • however, he developed erectile dysfunction and underwent an implantation of flexible penile prosthesis. (scielo.br)
  • Gupta A, Kenny D, Caputo M, Amin Z. Initial Experience with Elective Perventricular Melody Valve Placement in Small Patients. (rush.edu)
  • To compare renal function (51Cr-EDTA clearance) 48 hours post open-heart surgery (coronary bypass or valve surgery) in patients with impaired renal function after randomization to either nifedipine infusion at start of surgery and the following 24 hours or placebo (0.9% saline infusion). (clinicaltrials.gov)
  • Postoperative Renal Function After Open-Heart Surgery in Patients With Impaired Renal Function Preoperatively. (clinicaltrials.gov)
  • Usefulness of B-type natriuretic peptide to predict outcome of patients treated by transcatheter aortic valve implantation. (biomedsearch.com)
  • In developing countries such as Saudi Arabia, the prevalence of rheumatic fever is high, as is the percentage of female patients with mechanical heart valves and who are of child-bearing age. (biomedsearch.com)
  • To date, few reports are available of LMWH as sole anticoagulant in patients with mechanical heart valves. (biomedsearch.com)
  • What is the initial German multicenter experience with implantation of a JenaValve transcatheter heart valve (THV) for the treatment of pure aortic regurgitation in patients at high risk for surgery? (acc.org)
  • All patients were considered high risk for surgery (logistic EuroSCORE [European System for Cardiac Operative Risk Evaluation] 23.6 ± 14.5%), according to a local heart team consensus. (acc.org)
  • Expert consensus documents have highlighted that a multidisciplinary heart team approach is the most appropriate form of decision making in patients with aortic stenosis, 2 and is a class I recommendation in the management of coronary artery disease. (ahajournals.org)
  • 2 However, large numbers of high-risk patients are never referred or conventional valve surgery is deemed too risky for them. (cmaj.ca)
  • Continuing advances in heart valve prosthesis design and in techniques for implantation have improved the survival length and quality of life of patients who receive these devices. (europa.eu)
  • Percutaneous aortic valve implantation by transfemoral retrograde approach has been feasible in the majority of these patients with a high procedural success rate. (onlinejacc.org)
  • Two patients developed an atrioventricular block requiring the implantation of a permanent pacemaker. (onlinejacc.org)
  • All patients were discharged in asymptomatic status, with good prosthesis performance. (onlinejacc.org)
  • But over the last 5 years improvements in percutaneous approaches to implantation of prosthetic aortic valves have made it a potential therapeutic option for these patients. (mdedge.com)
  • Leon M, Smith C, Mack M. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. (springer.com)
  • These findings are not dissimilar to the reported 2-year results of the PARTNER IA (Placement of Aortic Transcatheter Valves 1A) trial in which PVAR improved in 31.9% and worsened in 22.7% of patients (9) . (onlinejacc.org)
  • This article presents examples of how to utilize the research output, to initiate academia-industry interaction, with the ultimate task of launching a new product: a smart heart valve prosthesis for pediatric patients. (springer.com)
  • Five patients with a previous medical history of erosion, infection and fibrosis were submitted to implantation of penile prosthesis lined by bovine pericardium. (scielo.br)
  • Patients with stenotic or regurgitant aortic valve disease appear to cleave multimers of Von Willebrand factor (HMW-multimer), presumably due to high-shear stresses and non-laminar flow. (bmj.com)
  • Bioprosthetic surgical valve dysfunction occurs frequently in elderly patients with severe comorbidities, which implies a high surgical risk in case of redo valve surgery. (bvsalud.org)
  • VIV procedures should be considered in patients with severely symptomatic prosthetic valve dysfunction with high surgical risk, after careful heart team evaluation. (bvsalud.org)
  • Prediction of the severity of aortic stenosis by Doppler aortic valve area determination: prospective Doppler-catheterization correlation in 100 patients. (springer.com)
  • The authors investigated the effects of postoperative sedation on the development of delirium in patients undergoing cardiac-valve procedures. (nih.gov)
  • Rheumatic fever is often associated with mitral valve disease and, despite the reduction in its incidence in developed countries, it is still very common in Brazil and other Latin American countries, particularly in younger patients [1] . (bjcvs.org)
  • Surgical treatment of the aortic valve is still the only definitive and effective treatment for the relief of left ventricular hypertrophy in patients with severe AS. (bjcvs.org)
  • Recent studies have shown that, after heart valve surgery, patients may require a more precise warfarin dosage than their non-surgical counterparts. (cdc.gov)
  • The study aim was to analyze the influence of certain clinical factors and CYP2C9 and VKORC1 gene polymorphisms on the efficacy of initiation of warfarin treatment in patients after cardiac valve surgery. (cdc.gov)
  • Following heart valve surgery, a total of 185 patients was genotyped for the CYP2C9*1, *2, *3 alleles and for VKORC1 (G-1639A) gene promoter polymorphism. (cdc.gov)
  • Percutaneous mitral valve repair (MVR) using the MitraClip system has become a valid alternative for patients with severe mitral regurgitation (MR) and high operative risk. (nih.gov)
  • Acute procedural success (APS, defined as successful clip implantation with residual MR grade ≤2+) was achieved in 85% of patients. (nih.gov)
  • Perceval valve was successfully implanted in 135 (97.1%) patients. (rbccv.org)
  • Five patients had permanent pacemaker as a result of complete heart block and mean postoperative drainage was 295 mL for isolated case and 457 mL for combined cases. (rbccv.org)
  • Assessment of the aortic annulus by multislice computed tomography, contrast aortography, and trans-thoracic echocardiography in patients referred for transcatheter aortic valve implantation. (springer.com)
  • The infected valve was native in 29 patients and prosthetic in 20 patients. (yonsei.ac.kr)
  • In two patients with prosthetic valve endocarditis due to Peptostreptococcus magnus , blood cultures in the BacT/Alert and BACTEC 9240 systems were signal negative. (asm.org)
  • According to multivariate analysis, only the extent of aortic-valve calcification was an independent predictor of outcome, whereas age, sex, and the presence or absence of coronary artery disease, hypertension, diabetes, and hypercholesterolemia were not. (nih.gov)
  • Papillary fibroelastoma of the aortic valve with temporary occlusion of the left coronary ostium. (biomedsearch.com)
  • The valve inside the conduit could be easily surgically extracted, leaving the conduit and coronary ostia intact. (minervamedica.it)
  • Abstracts: Successful treatment following percutaneous angioplasty (PTCA) and percutaneous trans aortic valve aortic valve stenosis and critical obstruction of the main left coronary artery is presented. (bvsalud.org)
  • Training in Structural Heart Disease: Call to Action. (rush.edu)
  • Predictors of survival in octogenarians after mitral valve surgery for degenerative disease: The Mitral Surgery in Octogenarians study. (rush.edu)
  • Aortic stenosis is a common heart disease that results in a fixed obstruction of the left ventricle and presents with angina, syncope, congestive heart failure or sudden death. (cmaj.ca)
  • He combines profound practical experience with his passion for curing heart valve disease. (arena-international.com)
  • Implantation of prosthetic cardiac valves to treat hemodynamically significant aortic or mitral valve disease has become increasingly common. (medscape.com)
  • Unfortunately, in over 4 million people each year, these delicate tissues malfunction due to birth defects, age-related deteriorations, and infections, causing cardiac valve disease. (techbriefs.com)
  • Cosmetic surgery has variety prosthesis to select from, not only to change the appearance of a feature for aesthetic reasons, but also to correct disfiguring from trauma or disease. (123helpme.com)
  • Aortic valve stenosis (with or without aortic regurgitation and without associated mitral stenosis) in adults in the Western world has been considered in recent years to most commonly be the result of degenerative or atherosclerotic disease. (nih.gov)
  • Aortic stenosis (AS) is the aortic valve disease most commonly found and is present in 4.5% of the population over 75 years. (bjcvs.org)
  • Severe aortic valve stenosis is a common cardiac disease among the elderly. (rbccv.org)
  • Aortic valve stenosis due to calcification of the valve leaflets is the most common valve disease in the developed world. (ahajournals.org)
  • 2 Calcification was earlier believed to be a passive degenerative process, but it is now recognized as an active disease process driven by the cells native to the aortic valve. (ahajournals.org)
  • Implantation of heart valve prostheses has been characterized as "replacing one disease with another. (ahajournals.org)
  • The patient was referred for urgent valve surgery. (bmj.com)
  • Primary efficacy endpoint is change in renal function, evaluated by 51Cr-EDTA clearance between 24 hours pre open-heart surgery and 48 hours post open-heart surgery. (clinicaltrials.gov)
  • Change in renal function after open-heart surgery, as measured by cimetidine refined serum creatinine clearance with measurements preoperatively and 2-6 hours, 20-24 hours and 44-48 hours postoperatively. (clinicaltrials.gov)
  • 6 Certain conditions, such as a highly calcified (i.e., "porcelain") aorta, mediastinal irradiation, liver cirrhosis or a need for reoperation with patent bypass grafts, may lower the threshold of risk for transcatheter valves, because of the well-recognized increased risks associated with these conditions in conventional surgery. (cmaj.ca)
  • Therefore, balloon valvuloplasty remains an emergency option as a bridge to aortic valve surgery. (bmj.com)
  • Having gained comprehensive knowledge in cardiac surgery, the development of heart valve prostheses and, finally, the new technology of transcatheter heart valves, he decided in 2009 to give up a very successful career as a cardiac surgeon and to start-up Transcatheter Technologies GmbH to develop a transcatheter heart valve system that is designed to increase the safety and durability of aortic valve implantation. (arena-international.com)
  • Combined heart surgery and lung resection remains a controversial issue. (medscimonit.com)
  • For bioprosthetic valves, the risk of repeat surgery was greater but the incidence of major bleeding was lower. (medscape.com)
  • Antegrade ascending aorta cannulation is adopted whenever possible (usually for aortic valve surgery). (escardio.org)
  • We present the case of a child who developed Aspergillus fumigatus mediastinitis months after heart surgery. (bvsalud.org)
  • Genetic variants of the angiotensin-converting enzyme (ACE) cascade may influence left ventricular myocardial mass (LVMM) regression after aortic valve surgery. (cdc.gov)
  • The study results suggested that, after cardiac valve surgery, by combining the clinical, genetic and anthropometric data of a patient, the warfarin dose may be estimated to 43% accuracy at the initiation of anticoagulant therapy. (cdc.gov)
  • Department of Cardiovascular Surgery, German Heart Centre of the Technical University Munich, Munich, Germany. (unboundmedicine.com)
  • 3 , 4 The only option for treatment is heart surgery with implantation of a valve prosthesis. (ahajournals.org)
  • The straightforward implantation technique and good acute results appear to suggest aortic regurgitation as a new indication for this device. (acc.org)
  • this can include stenosis or narrowing of the valve opening, regurgitation, the leakage of blood or prolapse, a billowing of the mitral leaflets. (si.edu)
  • Intra-operative 2D and 3D transesophageal echocardiographic predictors of aortic regurgitation after transcatheter aortic valve implantation. (springer.com)
  • Some other common implantation procedures are prosthetic cardiac valves, hip and knee implants, and dental implants. (123helpme.com)
  • A complication in anticoagulation using low-molecular weight heparin in a patient with a mechanical valve prosthesis. (biomedsearch.com)
  • when anticoagulation Controversy exists with regard to the appropriate and safe anticoagulation regimen of gravid women with mechanical heart valve prostheses. (biomedsearch.com)
  • BACKGROUND: Currently, the only commercial pre-assembled aortic valved conduits employ mechanical valves, requiring lifelong anticoagulation. (minervamedica.it)
  • To maintain enduring optimal biomechanical properties, the mechanical prostheses, based on carbon, metallic and polymeric components, require permanent anticoagulation, which often leads to adverse reactions, i.e. higher risks of thromboembolism, hemorrhage, and hemolysis. (europa.eu)
  • To date, no polymer coated mechanical prosthetic heart valve exists. (europa.eu)
  • The present research project aims to improve the hemocompatibility and long-term in vivo performance of mechanical prosthetic heart valves by reducing contact-induced thrombosis through bioactive polymer prosthetic valve surface coating. (europa.eu)
  • Andrew Capulli, Ph.D. and colleagues fabricated a valve-shaped nanofiber network that mimics the mechanical and chemical properties of the native valve extracellular matrix (ECM). (techbriefs.com)
  • As a leader in regenerative heart prostheses, Hoerstrup and his team in Zurich have previously developed regenerative, tissue-engineered heart valves to replace mechanical and fixed-tissue heart valves. (techbriefs.com)
  • The heart valve prostheses are either mechanical, requiring life‐long anticoagulation treatment, or based on biological material, which will degenerate and calcify after 10 to 15 years. (ahajournals.org)
  • Deformation dynamics and mechanical properties of the aortic annulus by four-dimensional computed tomography insights into the functional anatomy of the aortic valve complex and implications for transcatheter aortic valve therapy. (springer.com)
  • Another group of researchers have previously developed regenerative, tissue-engineered heart valves to replace mechanical and fixed-tissue heart valves. (longecity.org)
  • Department of Paediatric Cardiology and Congenital Heart Defects, German Heart Centre of the Technical University Munich, Munich, Germany. (unboundmedicine.com)
  • Treatment of aortic stenosis with a self-expanding, resheathable transcatheter valve: one-year results of the international multicenter portico™ transcatheter aortic valve implantation system study. (springer.com)
  • This initiative and document can furthermore be used as a model during current endeavors of applying definitions to other transcatheter valve therapies (for example, mitral valve repair). (onlinejacc.org)
  • A history of fever should raise the possibility of prosthetic valve endocarditis (PVE). (medscape.com)
  • Although P. magnus is the most frequently isolated GPAC from clinical specimens, as well as in pure culture and from normally sterile sites, it has been scarcely reported as a cause of septicemia or native- or prosthetic-valve endocarditis ( 7 , 8 ). (asm.org)
  • We report here two cases of prosthetic-valve endocarditis due to P. magnus which was recovered after culturing the surgically removed infected valve, whereas BacT/Alert blood cultures, incubated for 14 days, remained negative. (asm.org)
  • His main interest is developing innovative treatments for structural heart valve diseases. (arena-international.com)
  • In Brazil, valve diseases represent a significant number of hospital admissions for cardiovascular diseases, and rheumatic fever is the main cause, responsible for 70% of the cases [1] . (bjcvs.org)
  • (8) report the 1-year echocardiographic findings of the CoreValve U.S. Pivotal Trial, including a detailed dissection of valve size and function. (onlinejacc.org)
  • Echocardiographic assessment of valve stenosis: EAE/ASE reccomandations for clinical practice. (springer.com)
  • MitraClip implantation performed under echocardiographic and fluoroscopic guidance in general anaesthesia. (nih.gov)
  • Movie 6: Echocardiographic view after implantation of the second prosthesis. (icr-heart.com)
  • About 3% of the general population over 75 years of age have severe aortic stenosis, 1 and 2% of the general population at large have bicuspid aortic valves. (cmaj.ca)
  • Treatment of symptomatic severe aortic stenosis with a novel resheathable supra-annular self-expanding transcatheter aortic valve system. (springer.com)
  • The living cells are then eliminated from the scaffolds, resulting in an "off-the-shelf" human matrix-based prosthesis ready for implantation. (techbriefs.com)
  • The living cells are then eliminated from the scaffolds resulting in an "off-the-shelf" human matrix-based prostheses ready for implantation. (nanowerk.com)
  • 3 , 4 It is an important cause of congestive and sometimes intractable heart failure and of sudden cardiac death. (bmj.com)
  • 1 The stenotic aortic valve increases the ventricular afterload, leading to initial compensatory left ventricular hypertrophy and eventual progression to left-sided heart failure, if not treated. (bmj.com)
  • The typical symptoms of aortic stenosis include angina, syncope, and heart failure. (annals.org)
  • Herein, we discuss TandemHeart implantation via end-to-side femoral arterial grafting in a cardiac patient whose sepsis and multiorgan failure were complicated by coagulopathy and thromboembolism. (elsevier.com)